Modeling Macular Degeneration Using Quantitative Phenotypes by Hoffman, Joshua David




JOSHUA DAVID HOFFMAN 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements for 
the degree of 







Tricia Thornton-Wells, Ph.D. 
Jonathan L. Haines, Ph.D. 
Milam A. Brantley Jr., M.D., Ph.D. 
Chun Li, Ph.D. 









Copyright © 2015 by Joshua Hoffman 









To my wonderful wife Cassie, without your endless support and love, none of this would 
have been possible. 
 
In loving memory of Leonard Greenfield, a wonderful scientist and father-in-law. You will 





The body of research presented in this dissertation was supported by grants 
1F31AG044089 and 5T32GM080178 (to Joshua Hoffman), AG01972 (to William K. 
Scott), AG019085, EY012118, and EY023164 (to Jonathan Haines).  
Thank you to my dissertation committee at Case Western Reserve University 
and the Vanderbilt University Medical Center for their support and guidance of my 
dissertation research: Jonathan L. Haines (advisor), Milam Brantley Jr. (co-advisor), 
Chun Li (former chair), Tricia Thornton-Wells (chair), and David Samuels (director of 
graduate studies). I would like to thank Mark Van Grinsven and Clarisa Sanchez at the 
Radboud University Medical Centre, Netherlands, for their image analysis support.  
 Thank you to all the current members of the Haines lab: Jessica Cooke Bailey, 
Mariusz Butkiewicz, Yeunjoo Song, and Rob Igo. Thank you to all the former members 
of the Haines lab: Nathalie Schnetz-Boutaud, Ping Mayo, Olivia Veatch, Melissa Allen, 
Brian Yaspan, Anna Cummings, Laura D’aoust, and Mary Davis. Each of you made for a 
wonderful working environment throughout my studies. 
I would like to thank the study participants for providing us with this research 
opportunity. Thank you to the AMD and Amish ascertainment and clinical teams for 
collecting the subject related data and paving the way for our analyses. I would also like 
to thank the administrative staff in the CHGR who made the day-to-day possible. 
Thank you to my brother Jonathan Hoffman, my father Richard Hoffman, and my 
mother Barbara Wolfsdorf for their unending love and support. I would also like to thank 
my step-father Jack Wolfsdorf, a true inspiration for my career in research. 
iv 
TABLE OF CONTENTS 
                
                                             Page 
DEDICATION ................................................................................................................. iii 
ACKNOWLEDGEMENTS ............................................................................................... iv 
LIST OF TABLES .......................................................................................................... vii 
LIST OF FIGURES ....................................................................................................... viii 
LIST OF ABBREVIATIONS ............................................................................................ ix 
I.       INTRODUCTION .................................................................................................... 1 
Clinical Features of Age-Related Macular Degeneration .............................................. 1 
Epidemiological Studies of AMD .................................................................................. 8 
Treating AMD ............................................................................................................. 10 
Genetic Epidemiology of AMD ................................................................................... 12 
Studying Genetically and Environmentally Isolated Populations ................................. 22 
Conclusion ................................................................................................................. 23 
II. DESCRIPTION OF STUDY POPULATIONS AND QUALITY CONTROL 
PROCEDURES ............................................................................................................. 25 
Introduction ................................................................................................................ 25 
Use of Color Fundus Photography for Traditional Grading in AMD ............................. 27 
Cohort Grade Classification and Eligibility Requirements ........................................... 31 
Image Quality Control ................................................................................................ 36 
Discussion ................................................................................................................. 48 
III. GENETIC ASSOCIATION ANALYSIS OF DRUSEN LOAD .................................... 50 
v 
Introduction ................................................................................................................ 50 
Materials and Methods ............................................................................................... 52 
Results ....................................................................................................................... 57 
Discussion ................................................................................................................. 68 
IV. RARE COMPLEMENT FACTOR H VARIANT ASSOCIATED WITH AGE-RELATED 
MACULAR DEGENERATION IN THE AMISH ............................................................... 73 
Introduction ................................................................................................................ 73 
Materials and Methods ............................................................................................... 75 
Results ....................................................................................................................... 83 
Discussion ................................................................................................................. 87 
Acknowledgements .................................................................................................... 93 
V. CONCLUSIONS AND FUTURE DIRECTIONS ....................................................... 94 
APPENDIX .................................................................................................................. 102 
Appendix A:  Progression Slopes for 15 Additional Contributors to the Cumulative 
Genetic Risk Score .................................................................................................. 102 
Appendix B: Tabulated Results of Top Progression Quantitative GWAS Hits ........... 110 
Appendix C: Tabulated Results of Top Pathways from Paris .................................... 113 
Appendix D: Tabulated Results of Gene Enrichment Analysis (VEGAS) .................. 114 
REFERENCES………………………………………………………………………………..116  
vi 
LIST OF TABLES 
Table 1.1: Population Specific Prevalence of AMD ......................................................... 9 
Table 1.2: List of Common Variants Reaching Genome-Wide Significance in an AMD 
Meta-Analysis ................................................................................................................21 
Table 2.1:AREDS AMD Classification Scheme. .............................................................33 
Table 2.2: CWRU and HIHG Grading Scale ..................................................................35 
Table 3.1: Study Population Demographics ...................................................................58 
Table 3.2: Results of Single-Variant Association Analysis with Progression ..................64 
Table 4.1:Demographics for Amish and Non-Amish Datasets .......................................76 
Table 4.2: Genotyped Samples Utilized per Analysis Step ............................................82 
Table 4.3: AMD Self-report Pilot Study ..........................................................................83 
  
vii 
LIST OF FIGURES 
Figure 1.1: Symptoms of AMD Associated Vision Loss .................................................. 2 
Figure 1.2: Major Anatomical Structures of the Eye ........................................................ 3 
Figure 2.1: Age-related Maculopathy grading grid with reference circles. ......................29 
Figure 2.2: A-D: Drusen of Varying Severity and Type ..................................................30 
Figure 2.3 A-H: Example of Major Artifacts Present in AREDS Photographs .................39 
Figure 2.4 A-B: Quality Distribution of CWRU/HIHG and AREDS Images .....................41 
Figure 2.5: Effect of Quality Score on Drusen Calls .......................................................42 
Figure 2.6 A-B: Magnification Differences Between 30 and 50 Degree photographs .....43 
Figure 2.7: Results of CWRU/HIHG Replication Analysis. .............................................46 
Figure 2.8: Quantified Versus Categorized Drusen Area ...............................................47 
Figure 3.1: Correlation at Baseline between Eyes .........................................................59 
Figure 3.2: Correlation in Progression between Eyes ....................................................60 
Figure 3.3: Correlation of Drusen Area at Baseline and Risk Score ...............................62 
Figure 3.4: Correlation of Drusen Progression and Risk Score ......................................63 
Figure 3.5 A-E: Drusen Area Progression by Genotype .................................................65 
Figure 4.1: Diagram of the entire 13 generation all connecting pedigree of the Amish of 
Indiana and Ohio. ..........................................................................................................78 
Figure 4.2: Pedigree of nuclear family chosen for exome sequencing. ..........................79 
Figure 4.3: Cumulative Genetic Risk Score Analysis Across Amish and non-Amish 
Samples ........................................................................................................................84 
Figure 4.4: Variant filtration procedures .........................................................................86 
Figure 4.5 A-D: Multipoint linkage Results on Chromsome 1 .........................................88 
Figure 4.6: Identification of the least common ancestor .................................................92 
viii 
LIST OF ABBREVIATIONS 
AGDB Anabaptist Genealogy Database  
AMD Age-related Macular Degeneration 
anti-VEGF anti-Vascular Endothelial Growth Factor  
AOE Age of Exam 
AREDS Age-related Eye Disease Study 
ARMS2 Age-related Maculopathy Susceptibility Locus 2  
BPEI Bascom Palmer Eye Institute  
C2 Complement Component 2 
C3 Complement Component 3  
CAM Cell Adhesion Molecules 
CAMP Collaborative Aging and Memory Project  
CATT Age-related Macular Degeneration Trials 
CD226 Cluster of Differentiation 226 
CFB Complement component B  
CFH Complement Factor H  
CFHR1 Complement Factor Related 1 
CFHR1 Complement Factor Related 3 
CFI Complement Factor I  
CWRU Case Western Reserve University  
dbGAP Database of Genotypes and Phenotypes 
DHA Omega-3 long-chain Polyunsaturated Fatty Acids  
DUEC Duke University Eye Center  
EPA Eicosapentanoic acid 
EVS Exome Variation Server  
FDA Food and Drug Administration 
GA Geographic Atrophy  
GATK Genome Analysis Toolkit  
GERP Genomic Evolutionary Rate Profiling  
HIHG Hussmann Institute for Human Genomics 
HLOD Heterogeneity Log-of-odds  
HTRA1 Serine Protease Inhibitor 1  
indel Insertion-deletion 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LD Linkage Disequilibrium  
LOD Log-of-the-odds  
MQLS Modified Quasi Likelihood Score Statistic  
NFASC Neurofascin  
NRXN1 Neurexin  
OCT Optical-coherence Tomography  
RPE Retinal Pigment Epithelial Layer 
SAGA Swiss Anabaptist Genealogical Association  
ix 
SCR Short Consensus Repeat  
VEGAS Versatile Gene-based Association Study 











Clinical Features of Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is a debilitating disorder that is 
responsible for progressive loss of central vision. As the name implies, AMD affects the 
central portion of the retina, known as the macula. The macula is topologically located 3 
mm temporal to the optic disc and has a diameter of roughly 6mm. The macular region is 
responsible for having the highest visual acuity. AMD is a phenotypically heterogeneous 
disorder and involves disruption of many aspects of normal retinal anatomy and 
physiology.  These disruptions can be characterized into non-neovascular AMD and 
choroidal-neovascular AMD. An example of severe AMD as experienced by subjects with 
the disorder is depicted in Figure 1.1. The known cellular components and layers that play 
a significant functional role in AMD are the retinal pigment epithelial (RPE) layer, the 
Bruch’s membrane, and the choriocapillaris (Figure 1.2). The RPE layer plays a critical 
supportive role in normal retinal physiology. The RPE is responsible for regeneration of 
visual pigments and maintenance of the Bruch’s membrane and the overlying rods and 
cones through transportation of fluids and waste between the choriocapillaris and 
photoreceptor layer. The Bruch’s membrane is an intracellular matrix that acts as a 
scaffold for the RPE and choriocapillaris, working to regulate cell survival within these two 
layers1. The choriocapillaris, which is a layer of the choroid, is a network of capillaries that 
acts as the vascular system for the outer retina. 
1 
Figure 1.1: Symptoms of AMD Associated Vision Loss 
In the left hand image is an example of a person normal eyesight. The right hand image represents an individual with 




Figure 1.2: Major Anatomical Structures of the Eye 
A) Diagram of a transverse section of the eye taken through the optic nerve. B) Highlights the major retinal cellular structures that 
undergo AMD associated physiological changes. Figure is adapted from Campagne et al. 20142. 
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Early stages of Dry AMD 
Of the factors that present with AMD, drusen is one the major clinical hallmarks 
and AMD is rarely diagnosed in their absence3. Drusen are extracellular deposits that 
form between the retinal pigment epithelial (RPE) layer and the Bruch’s membrane. 
Drusen show high variation in morphology and number across individuals and eyes.   
Drusen morphology can be characterized into hard and soft4. Hard drusen are typically 
less than 63 um in diameter and are observed as small yellow nodules with discrete 
borders. Soft drusen are commonly greater than 125um in size and take on a pale 
yellow to greyish appearance and unlike hard drusen, soft drusen tend to have indistinct 
borders.  Subjects may present with small to intermediate drusen throughout their lives 
and not progress past this stage, while others may form complexes of hard and soft 
drusen that continually expand over time. It is also important to make the distinction that 
individuals may present with small drusen and not be considered AMD case subjects. 
The biochemical composition of drusen is complex and host a range of 
polysaccharides, glycosaminoglycans, and lipid components. A major proportion of 
drusen composition is esterified and non-esterified cholesterol. Protein profiling has 
estimated 129 different proteins present within hard and soft drusen with some of the 
common proteins shared between AMD and non-AMD donor eyes being apolipoprotein 
B and E (APOE), vitronectin, complement factor H, TIMP3,and complement components 
C3,C5,C8, and C94-6. Gene expression analysis of drusen associated mRNA has shown 
enrichment for ApoE, vitronectin, TIMP3, and complement components C3, C5, and C93, 
6.  
The understanding of drusen formation is ongoing, with many theories existing 
on how drusen biogenesis may occur. One of the major theories is that drusen formation 
is a result of inflammation response activation of the complement cascade through 
immune related signals from the RPE as many of the proteins identified within drusen 
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are upregulated during immune response3. It has also been suggested that drusen 
formation may be a result of an oxidative stress response3, 7, 8. Oxidative modification of 
extracellular waste produced by the RPE may lead to anchoring of protein components 
to the Bruch’s membrane causing an expansion of drusen over time3.   
 
Late Stages of AMD 
Severe dry AMD is characterized by the presence of geographic atrophy (GA). 
GA is the result of RPE layer atrophy or cell death and is typically progressive in 
manner. Due to the supportive nature of the RPE cells, death of this layer is a large 
factor in secondary loss of photoreceptors and the choriocapillaris leading to 
deterioration of visual acuity. GA can be uni-focal or multi focal in nature. In unifocal GA, 
atrophy is localized to a single feature that then spreads outward overtime. As GA 
progresses it tends to take on a horseshoe appearance, typically surrounding the fovea 
and eventually this pattern forms a ring later in progression. In multi-focal GA several 
areas of atrophy present themselves within the macular and spread over time (Figure 
1.3 B). In some instances, these multiple areas of atrophy may coalesce into a single 
atrophic area. Both types of atrophy can later spread to include the foveal region leading 
to central vision loss9, 10. GA progression in this manner may take up to years to develop.   
Different rates of geographic atrophy progression have been reported, with Holz et. al. 
showing a median geographic atrophy progression rate of 1.52mm2/year and Sunnes et. 
al. reporting 2.2 mm2/year11, 12. Although dry AMD makes up to 20% of all AMD patients 
that have visual acuity less than 20/200, most of these patients do not have severe 
vision loss10.  
The more common form of severe vision loss is wet AMD. Wet AMD is thought to 
arise through a multifactorial process. As part of this process it is hypothesized that an 
immune response resulting from damage or stress may cause the production of pro-
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angiogenic factors such as vascular endothelial growth factor (VEGFA) by the RPE, 
leading to choroidal neovascularization. These new blood vessels stemming from the 
choriocapillaris which are thin and weak, break through a compromised Bruch’s 
membrane and begin to leak blood and fluid into the space separating the Bruch’s 
membrane and the RPE layer13-15. This buildup of fluid can cause a blurring of vision at 
first, and potentially RPE layer detachment. Unlike geographic atrophy, onset of vision 
loss is a rapid process and can result in blindness of the affected eye within months of 
first signs and symptoms1.  Figure 1.3 depicts examples of the clinical hallmarks of AMD 
as described above. 
It is important to note that although AMD may be characterized into different 
stages and distinct phenotypes, they are all thought to be part of one disease process. 
Central to this, we find that both wet and dry AMD may co-occur in the same eye, and 
the underlying risk factors and tissue types affected appear to overlap. This is 
highlighted by the degenerative changes occurring in the Bruch’s membrane and RPE 
layer during the early to intermediate stages of the disease that then may lead to GA or 
choroidal neovascularization. The observation that drusen are a risk factor for both 
severe dry and wet AMD provides further evidence of the interplay between these 2 
phenotypes. Research into the potential pathophysiological drivers for the different AMD 




Figure 1.3 A-D: Examples of AMD Severity 
A) Intermediate AMD depicted with soft drusen centered on the fovea and 
surrounded by small hard drusen. B) Multifocal GA observed as multiple distinct 
areas of atrophy C) Unifocal GA observed as a flower pattern spreading outwards 




Epidemiological Studies of AMD 
 
Prevalence estimates for AMD have been carried out for different racial/ethnic 
populations and varying geographic regions throughout the world. A common finding 
throughout AMD epidemiological studies is that this disease is relatively rare in 
individuals under the age of 55, but that prevalence increases dramatically with 
increasing age groups.  Recent reports indicate that there are currently over 1.5 million 
individuals with AMD in the United States16. In a meta-analysis carried out by “The Eye 
Disease Prevalence Research Group”, it was determined that the combined prevalence 
estimates for both wet and dry AMD in the United States are 1.52% and 16.39% for ages 
70-74 and 80, respectively16.  
Variation in prevalence of AMD has been identified between populations of 
different ancestral backgrounds16-18. In a study examining the prevalence of AMD in the 
Multi-ethnic Study of Atherosclerosis (MESA), Klein et al. observed individuals of 
European ancestry as having the highest overall prevalence of AMD in the United States 
when compared to individuals of African American, Chinese, and Hispanic descent 
(Table 1.1; p <0.001)16. When AMD was subdivided into wet AMD and dry AMD, the 
authors observed a significant increase in frequency of wet AMD in subjects of Chinese 
descent versus European descent (Table 1.1)16. The authors also observed a lower 
prevalence of wet AMD in African-American versus Caucasian populations, although the 
presence of large soft drusen along with retinal pigmentary changes seem to occur at 
similar time points in both racial groups16. 
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Table 1.1: Population Specific Prevalence of AMD 
For each racial/ethinc group used from the MESA cohort, prevalence estimates of the different AMD subtypes 
were calculated per separate age and gender groups. Taken from (Klein et al. 2006)16. 
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Environmental and Clinical Risk Factors Associated with AMD 
Age is currently the biggest risk factor for developing AMD. The disease is the 
least common in individuals under the age of 55 and the most common in individuals 
over the age of 758,9,19-22. Studies examining the risk associated with gender have 
identified conflicting evidence of gender associated risk of AMD16, 22, 23. Some studies 
have shown a significantly higher prevalence of AMD among females in Caucasian 
populations, especially in older ages groups (age at exam > 60)16, 22, 23. When examining 
subjects aged between 55-84, Smith et al. showed a significant increase in risk for 
females (OR = 1.15)24.  The second major environmental risk factor that has been 
associated with AMD consistently is smoking, with a relative risk between 2-4 for 
individuals that smoke compared to those that have never smoked25-30. Cross sectional 
and longitudinal studies carried out by the Blue Mountain Study group with respect to 
cardiovascular risk factors for AMD have shown that high-density lipoprotein and 
cholesterol may be inversely related to AMD risk, and that presence of cardiovascular 
disease such as stroke, myocardial infarction, and angina may be a risk factor31. The 
effects of hypertension on a person’s risk for developing AMD have been contradictory, 
but BMI has been identified as a risk factor for AMD32, 33. Other studies examining the 




To examine the role that vitamin supplementation may play in slowing AMD 
progression, a clinical trial carried out by the Age Related Eye Disease Study (AREDS) 
research group looked specifically at the effect of high doses of anti-oxidants and zinc on 
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AMD progression and visual acuity37. The results showed that subjects who were put on 
a high-antioxidant plus zinc nutritional supplementation plan had a significantly reduced 
risk of progressing to advanced AMD versus the placebo group (OR = 0.72), but had 
little effect on progressing from early to intermediate stage AMD37. AREDS 2, examined 
the potential protective impact of lutein + zeaxanthin, omega-3 long-chain 
polyunsaturated fatty acids (DHA) and eicosapentanoic acid (EPA) on AMD 
progression38. The results of this study have recently been completed and showed that 
changes to the  current AREDS formulation significantly altered AMD progression 
compared to placebo38.  Results of the AREDS2 trial suggested replacing beta-carotene 
with lutein and zeaxanthin while the addition of fatty acids had no significant effect38. 
Although the use of vitamins and anti-oxidants has shown some promise in 
slowing AMD progression, the major tool used in the treatment of AMD has been the use 
of anti-Vascular Endothelial Growth Factor (anti-VEGF antibodies) wet AMD. Two of the 
major anti-VEGF treatments currently being used in the clinical setting are ranibizumab 
(Lucentis) and bevacizumab (Avastin) as an off-label drug. Lucentis is a humanized 
monoclonal antibody fragment that binds to and blocks all forms of VEGF-A. In one of 
the pivotal  clinical trials, 95% of individuals receiving intravitreal injections of 
ranibizumab had lost less than three lines on the standard visual acuity chart for the 
treated eye after 1 year compared to only 62% of those receiving placebo injections39 . 
Avastin, which is also a humanized monoclonal antibody, was originally Food and Drug 
Administration (FDA) approved for the treatment of colon cancer, but was found to slow 
progression of wet AMD in subjects receiving this drug. In the “Comparison of Age-
related Macular Degeneration Trial” (CATT), which examined the efficacy of both Avastin 
and Lucentis, both drugs had similar impacts on AMD treatment41. One of the newer 
treatment regimes that has recently been approved by the FDA is aflibercept (EYLEA). 
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This molecule is a VEGF trap, preventing VEGF from binding to its receptors. EYLEA 
has the benefit of increased time between injections compared to Avastin and Lucentis, 
with dosages occurring once a month in the first 3 months of treatment followed by 
bimonthly injections thereafter.  
 
Genetic Epidemiology of AMD 
 
Although AMD is a complex, phenotypically heterogeneous disorder, the 
presence of a genetic role for AMD has been well documented through twin studies and 
familial aggregation studies. In a familial aggregation study carried out by Seddon et al., 
first-degree relatives of those affected with late AMD were at an increased odds of risk 
(OR = 2.4) when compared to families that did not have members with AMD31. A twin 
study carried out by Seddon et. al. in 840 twins estimated the heritability of intermediate 
AMD to be 0.67 and advanced AMD to be 0.7142. The group also reported an overall 
AMD heritability estimate of 0.4642. Similar findings were reported by Hammond et. al. 
when their study examined 406 twin pairs that produced heritability estimates between 
0.45 to 0.81, depending on the severity of the disease43.  
Early Genetic Studies of AMD 
One of the first major tools used to dissect the genetic architecture of AMD were 
genome-wide linkage studies. Genome-wide linkage analysis is carried about by 
examining the segregation of genetic markers spaced throughout the genome with a 
given trait or disease within families. Generally, a log-of-the-odds (LOD) score greater 
than three is considered significant evidence for linkage.   One of the earliest linkage 
screens carried out for AMD was in a single 21 family member pedigree by Klein et al. 44. 
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Linkage analysis in this family identified a maximum multi-point LOD score of 3.0 in the 
1q25-q31 region that segregated in a dominant fashion. Following the work by Klein et 
al., several other linkage screens were carried out proposing regions 9q31, 10q26, 
12q23, 15q21, 16p12, 17q25, and 22q13 as showing evidence of linkage45-49. A meta-
analysis carried out by Fisher et al. to examine previous linkage peeks that were only 
moderately associated with the AMD phenotype, identified strong linkage on 
chromosome 1q and 10q26, and significant evidence of linkage on chromosomes 
2p,3p,4q,12q, and 16q50.  
With the combination of success found in linkage screens for AMD and its highly 
heritable nature for a complex common disease, AMD provided a strong candidate for 
genome-wide association studies (GWAS). GWAS arose out of the completion of the 
Human Genome Project in 2000 and the estimation of linkage disequilibrium across the 
genome by the International HapMap Consortium in 200251, 52. Through these efforts, 
panels made up of single marker polymorphisms (SNPs) ranging from 100,000 to over 
1,000,000 markers were created to interrogate the genome. GWAS allowed for 
hypothesis-free association testing of genetic markers with disease across the entire 
genome, and thus provided a powerful statistical approach for identifying the contribution 
of unknown common genetic variation to disease.   
The application of GWAS and fine mapping of SNPs to AMD proved successful 
with several studies publishing association results simultaneously in 200550, 53-57. These 
studies implicated a non-synonymous variant in a previously reported linkage peak that 
causes a serine to histidine amino acid change (Y402H) in Complement Factor H 
(CFH)53-56. Several variants within the10q26 locus were also shown to be strongly 
associated with AMD and implicated the region containing age-related maculopathy 
susceptibility locus 2 (ARMS2) / Serine Protease Inhibitor 1 (HTRA1) as the genes of 
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interest50, 57. Most of the success of GWAS in AMD can be attributed to the large 
magnitude of effect that these variants exhibit, and the frequency of the risk alleles in the 
population, a property that is relatively rare in complex common diseases. The CFH risk 
allele was proposed to have an estimated OR of over 2.5 per allele and a risk allele 
frequency of approximately 0.54 in cases and 0.36 in controls53-56. The variants harbored 
in ARMS2/HTRA1 had an estimated allelic OR of 2.7 and a risk allele frequency of 0.42 
in cases and 0.20 in controls50, 57. 
Genome-wide linkage and association analyses have implicated a multitude of 
variants across the entire genome as risk factors for AMD. An integrative phenotype-
genotype search of known association results returned 331 SNPs in or around 225 
different genes across all 22 autosomes and the X chromosome, highlighting the 
potential extent of genetic signals contributing to AMD risk (Figure 1.4).  
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Figure 1.4: Genetically Associated AMD Loci 
Ideogram showing variants genetically associated with AMD. Arrows point to specific genes. * 
 
 
*http://www.ncbi.nlm.nih.gov/gap/phegeni#GenomeView; accessed January, 2015 
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 Complement Factor H 
CFH is located on chromosome 1 within a cluster of genes that encode the 
regulatory components for the activation of C3 and has been one of the most 
significantly replicated genes to be associated with AMD to date. CFH is a glycoprotein 
that plays an inhibitory role within the complement pathway. CFH selectively binds and 
inactivates complement component C3b thereby preventing the continuation of the 
complement cascade.  
The Y402H variant rs1061170 in CFH was one of the first SNPs found to be 
associated with AMD 45-49. The magnitude of the effect of this variant on AMD risk is 
considered substantial, with Haines et al. reporting odds ratios between 2.45 and 5.57 
for having one or two copies of the risk allele respectively55.  Klein et al. and Edwards et 
al. also presented similar finding with reported odds ratios around 2.7 per risk allele53, 56, 
58. 
Further work carried out at the CFH locus suggests that there may be other 
disease-associated variants present throughout the gene. In a study carried out by Li et 
al. examining 84 polymorphisms in and around the CFH locus, 20 polymorphisms 
showed stronger association with AMD than the Y402H variant 43. They also observed 
that no single polymorphism could explain the role of CFH in AMD risk, but instead that 
there was the presence of four common haplotypes along with multiple rare haplotypes 
with two of the common haplotypes being associated with AMD risk and two being 
protective. The pathophysiological role that CFH plays in AMD may be explained in part 
due to the observation of complement proteins including CFH within drusen, as it is 
thought that local inflammation and activation of the complement pathway may in some 
part be responsible for AMD pathogenesis. In work by Clark et al., CFH was found to be 
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the major regulator of the complement cascade at the Bruch’s membrane51. Further work 
showed the highly associated Y402H variant resulted in reduced binding of CFH to the 
Bruch’s membrane, thus potentially leading to increased activation of the complement 
cascade and damage to this layer59, 60. 
 
Other Complement Pathway Associated Genes 
CFH has not been the only complement pathway gene identified as a contributor 
to AMD risk. In a case-control study that interrogated single nucleotide polymorphisms 
across the Complement component 3 (C3) and Complement component 5 (C5) loci, 
Yates et al. showed that a polymorphism in C3 to be significantly associated with AMD 
with an odds ratio of 2.6 for individuals that were homozygous for the risk allele61. This 
polymorphism has been confirmed by an independent study carried out by Maller et al. 
in two independent Caucasian populations62. Like CFH, C3 localizes to drusen. 
Complement component B (CFB) and Complement component C 2 (C2), located in the 
major histocompatibility complex III region, are two other genes that have been 
implicated in AMD. The minor allele of in C2/CFB has been found to be associated with 
reduced risk (OR = 0.57) 63. In a case-control haplotype analysis carried out by Gold et 
al., one common risk haplotype (OR = 1.32) and two protective haplotypes (OR = 0.45 
for H7 and 0.36 for H10) were identified at the CFB/C2 locus63. Real-time PCR 
performed by this group also showed the presence of CFB and C2 in ocular drusen and 
within the Bruch’s membrane63. The protective role of one of the CFB/C2 haplotypes 
may be linked to reduced hemolytic activity within the complement cascade, and as such 
a reduction in inflammation response. In addition to the CFH protective haplotypes, copy 
number variation analysis identified a complement factor related (CFHR1/CFHR3) 
deletion that confers protection against AMD64. Functional analysis of the CFHR3 
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deletion identified this locus as an inhibitor of C3 convertase activity, thus playing a role 
in the complement pathway65. 
 
Age-Related Maculopathy Susceptibility 2 and Serine Protease Inhibitor 1 
  ARMS2 and HTRA1 located on chromosome 10 is another major locus 
implicated in AMD pathogenesis. There has been much debate as to the causal locus 
inferring AMD risk, as the 2 associated variants, rs11200638 in HTRA1’s promoter and 
rs10490924 in ARMS2 (A69S)  are located only 6.6 kb away from another, and LD 
between these variants is high (D’=0.97,r2 = 0.93)66, 67. As such, these genes are 
commonly referred to as a single locus (ARMS2/HTRA1). In an in-depth case-control 
analysis of the 10q26 locus, Yang et al. reported ORs as high as 6.5 for the homozygous 
genotype at SNP rs1120063868. At the time, the authors estimated that this SNP 
contributes a population-attributable risk close to 50% for AMD, and when taken in 
conjunction with the CFH variant Y402H, population attributable risk may reach as high 
as 71%68.  
Functional analysis of the HTRA1 gene suggests that it may be involved in the 
regulation of extracellular matrix proteoglycan degradation. Overexpression of HTRA1 
may lead to a reduction in the integrity of the Bruch’s membrane allowing for the 
invasion of choriocapillaris across the extracellular matrix, a feature that is present in the 
wet form of AMD. This potential physiological role is supported statistically by genetic 
association analyses that have shown differences in the magnitude of effect when 
adjusting late AMD subjects for the presence of GA or wet AMD69, 70. In these analyses, 
the authors observed that CFH attributed higher risk to subjects with bilateral GA 
compared to subjects with bilateral wet AMD. The authors described variants in 
ARMS2/HTRA1 as conferring higher risk to bilateral wet AMD. Although these 
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magnitude of effect differences exist, risk variants in these genes still show high 
statistical significance with both phenotypes69, 70. Expression analysis of the HTRA1 
gene in the presence of the rs11200638 variant has led to conflicting results, with some 
studies suggesting an association with increased mRNA expression levels while other 
studies have not been able to replicate these results71-74, 74, 75.  
Little is known about the biological role of ARMS2. Evolutionarily it is thought to 
have arisen recently within the primate specific lineage76. Fritsche et al. identified an 
insertion-deletion (indel) polymorphism within ARMS2 conferring risk in the presence of 
at least one copy of the deletion (OR = 2.9)76. It was shown that harboring two copies of 
the deletion resulted in undetectable levels of ARMS2 in subject donor eyes. Fritsche et. 
al. also observed that ARMS2 localized to the mitochondria and that ARMS2 may act 
through mitochondrial mediated pathways76. Contradictory to this study, Wang et al. 
reported that ARMS2 localized to the cytosol and not the mitochondria of ARPE-19 and 
COS7 cells. In a separate study by Wang et al., the A69S SNP was observed to be in 
high LD with the indel and did not correlate with ARMS2 mRNA expression77. 
 
Contribution of Rare Variants to AMD 
The application of high-throughput sequencing has allowed investigators the 
opportunity to shift from common variant to rare-variant analyses for the study of AMD to 
identify the missing contributors of AMD genetic risk78, 79. Recent studies have identified 
a number of rare variants in known AMD associated genes that confer risk for AMD. Ven 
et al. identified a highly penetrant rare mutation in complement factor I (CFI) that 
associated with AMD risk with an OR of 22 in a European-based sample80. Functional 
analysis showed reduced expression of CFI and less efficient degradation of C3b in 
carriers of this variant. In a whole-genome sequencing study examining 2,200 Icelandic 
subjects, a rare non-synonymous C3 variant was identified conferring an OR of 3.45 and 
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follow up functional analysis showed reduced binding of C3b to CFH81. The authors were 
able to replicate this statistical association in an independent European sample where 
an even larger magnitude of effect was observed (OR = 4.22).  
In a recent analysis in which the authors sequenced all genes that harbor 
common variants reported to be associated with AMD in over 1,600 cases and 750 
controls, the authors identified a significant enrichment of variants in cases compared to 
controls based on gene burden tests82. Interrogation of individual variants within these 
genes showed significant associations with rare-variants in CFI, C3, and C982. In a 
functional analysis of the rare C3 variant, the authors showed reduced inactivation of C3 
by CFH and CFI82. 
 
Common Variants of Low Effect 
 Although the bulk of common variants of modest to large affect have been 
identified, a recent meta-analysis was completed to identify the remaining common 
genetic contributors to AMD through a large meta-analysis69. As one of the most 
significant meta-analysis to date in terms of subject sample size, the authors replicated 
12 previously identified AMD loci and reported 7 new loci of minor to modest effect in 
over 17,000 cases and 60,000 controls69. The authors predicted that these 19 common 
variants contribute 15% to 65% of the total genetic variation attributed to AMD risk based 
on prevalence estimates of 1% to 30%. The seven new loci by themselves only predict 
to contribute 1% of the genetic variation explained for AMD69. The effect sizes of the 
replicated and novel loci are shown in Table 1.2.  Examination of these 19 loci in a 
cumulative genetic risk score analysis showed that these 19 loci can modestly predict 
AMD disease status with an area under the curve (AUC) of 0.74.
20 
Table 1.2: List of Common Variants Reaching Genome-Wide Significance in an AMD Meta-Analysis 





Studying Genetically and Environmentally Isolated Populations 
 
The study of a complex disease such as AMD introduces a number of genetic, 
phenotypic, and environmental variables that must be dissected to find contributing risk 
factors to disease. A majority of studies that examine genetics of AMD take large, 
population based approached to identify attributable genetic risk loci. One measure of 
reducing this heterogeneity is through the study of environmentally and genetically 
isolated founder populations. With these types of populations, we observe a more 
homogenous environmental and genetic background, potentially increasing our power to 
detect genetic associations within complex diseases. The Amish communities of Indiana 
and Ohio are one example of an isolated study population that we study extensively. 
The Amish represent a genetically isolated founder population that emigrated 
from Western Europe in two waves beginning in the early 1700’s. During the first wave, 
members of the Swiss Anabaptist Community immigrated to Pennsylvania. In a second 
wave of immigration occurring in the early 1800’s, members of the Pennsylvania Amish 
community moved to Holmes County in Ohio. In addition to the local establishment of 
this new community in middle Ohio, another group of immigrants arriving from Western 
Europe established communities in Elkhart LaGrange and Adams County in Indiana83, 
84.These immigration patterns created population bottlenecks, causing a reduction in 
genetic variation within these new communities. The Amish live a strict religious and 
cultural lifestyle, typically marrying within the faith and generating large families. This 
characteristic, in addition to relatively recent founder event that created this community, 
creates a more genetically and environmentally homogenous group as compared to the 
general population.  
22 
Another advantage of using the Amish population for genetic studies is their 
extensive genealogical record keeping.  Records on members of the Amish community 
are continuously updated in the Anabaptist Geological Database (AGDB) and the Swiss 
Anabaptist Genealogical Association (SAGA)85, 86. This record keeping allows all 
members of the community to be connected into a single pedigree. This extensive 
pedigree information proves valuable for measuring degrees of relationship and querying 
extended families.  
The use of this Midwestern Amish population has already proved successful in 
elucidating genetic loci in complex disease as applied to studies of late-onset 
Alzheimer’s disease (LOAD) and Parkinson Disease (PD)87-89. Through linkage and 
association analysis, Cummings et. al. identified CTNNA2 as a potential risk locus for 
LOAD and additionally identified 3 other loci with log odds (LOD) score over 389. It was 
also shown that the major risk allele in APOE was significant in this population, showing 




AMD is a complex and debilitating disorder with many environmental and genetic 
components contributing to the overall risk of developing the disease. As a disease of 
aging, we can expect that the number of new cases to appear in the coming years to 
increase at an alarming rate as a result of technological advances in medicine increasing 
average life expectancy. Continued understanding of the implications that both known 
and unknown genetics risk factors play in AMD is necessary. Even with the success that 
genetic and epidemiological studies have brought to understanding AMD risk, the 
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functional roles of these variants have proven difficult to discern and generally are 
conflicting. Much of this complexity may be explained by the seemingly high overlap 
between the AMD phenotypes and physiological pathways that are involved in the 
manifestation of disease. To dissect this interplay, it is necessary to perform phenotype 
specific analyses of AMD. With drusen playing such a pivotal role in AMD diagnosis and 
risk for disease progression, we explore the potential impact of known genetic variation 
on this phenotype (Chapter II & III).  
Most, if not all, the common variants that contribute at least modest effects to 
AMD have been identified.  It is now also of importance to away at the unknown genetic 
component of AMD through rare variant analysis.  In chapter IV, we explore the impact 
of rare genetic variation on AMD using an isolated founder population that has shown 
reduced cumulative genetic risk when put in context of the major known AMD genetic 
risk loci.   
 Although there has been some success in the development of new treatments 
for AMD, most if not, all are targeted towards the advanced stages. Understanding the 
contribution of known genetic variation to the pathological changes observed in AMD 
and identifying the missing genetic component are paramount. The elucidation of these 
processes will allow us to continue the development and the refining of how AMD risk is 









Fundus photographs used in our analyses were selected from two separate 
datasets: one coming from the Age-related Eye Disease Study (AREDS) and a second 
one from the combined dataset from Case Western Reserve University (CWRU) and the 
Hussman Institute for Human Genomics (HIHG). The AREDS dataset was used in our 
study as it was available within the “Database of Genotypes and Phenotypes” (dbGAP). 
Through the contribution of AREDS to dbGAP, a wealth of deep phenotype data across 
thousands of individuals is publicly available. In total, 650 variables ranging from 
demographic data such as race, sex, and age, to clinical measures such as blood 
pressure, cholesterol and history of current prescription drug use, as well as history of 
other eye or non-eye related disorders were made available. Ascertainment of the 
CWRU/HIHG dataset has been ongoing for over the past 10 years and is continually 
expanding. Subjects were recruited from Durham North, Carolina; Nashville, Tennesee; 
and Naples and Palm Beach, Florida. CWRU/HIHG is a clinic based sample and was 
originally focused on collecting multiplex families for the study of AMD. Shifting study 
designs has led to the collection of subjects for case-control and longitudinal treatment 
and progression studies. A further description of the CWRU/HIHG dataset can be found 
in chapter III. The AREDS dataset will be discussed in further detail concerning sample 
collection, grading criteria, and inclusion/exclusion criteria below. 
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AREDS Study Design 
AREDS was designed to identify the impact of high doses of antioxidants and 
zinc on cataracts and AMD.  AREDS was divided into three separate phases and 
spanned a total of 16 years. The major goal of phase one was to design the study and 
enroll and screen subjects for eligibility and took place from March 1990 to October of 
1992.   
Phase two was the clinical trial portion of the study, which aimed to define the 
role of antioxidants and zinc on AMD and cataract progression. Phase two took place 
from November 1992 through September 2001 in which time subjects deemed eligible in 
phase one, were observed for up to seven years. During phase two, study participants 
were assigned to a treatment regimen consisting of either antioxidants, zinc, a 
combination of antioxidants and zinc, or a placebo. Subjects that had a diagnosis of less 
than intermediate AMD were not assigned to the zinc group due to the risks associated 
with zinc intake. Description of the AREDS grading scale will be discussed further in the 
grading classification section of this chapter. As part of the phase two study design, 
subjects were followed-up every six months with a clinical exam. Macular photographs 
were taken at the enrollment and randomization visit, which was set as the baseline, 
then two years from baseline. Following the two-year visit, photographs were taken 
annually. If visual acuity dropped by more than 10 letters during the time from the 
baseline visit to any of the follow-up visits, a non-annual photograph was required. In 
total, subjects’ median follow-up time for phase two was 6.5 years. The major outcome 
variables that were measured during phase two were the morphological changes 
associated with drusen, geographic atrophy, and choroidal neovascularization, along 
with changes in visual acuity and function. 
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The objective of phase three was to understand the natural history of AMD 
progression by extending the clinical trial for another five years.  By increasing the 
observation time of subjects, the AREDS investigators’ hypothesis was that more 
subjects would progress from the control group to cases, and controls that did not 
progress would make a valuable control cohort due to their non-progressing to slowly 
progressing nature. Another major objective of the phase three trial was to generate new 
grading scales to better predict disease progression. As an extension of phase two, 
subjects continued to be seen annually for ophthalmic examination although subjects 
were not required to continue their previous treatment regimen. 
Ascertainment and clinical exams of subjects for AREDS took place at 11 
different clinical centers throughout the U.S. These centers included the Eye Center at 
Memorial in New York, Associated Retinal Consultants in Pennsylvania and Michigan, 
Devers Eye Institute in Oregon, Emory University in Georgia, Massachusetts Eye and 
Ear Infirmary, National Eye Institute Clinical Center in Maryland, University of Pittsburgh 
Eye and Ear Institute in Pennsylvania, Ingalls Memorial Hospital in Illinois, Johns 
Hopkins in Maryland, Elman Retina Group in Pennsylvania and Maryland, and the 
University of Wisconsin. Although routine clinical follow-up and fundus photography was 
carried out at these 11 institutions, grading of fundus photographs was completed at a 
centralized reading center at the University of Wisconsin. 
 
Use of Color Fundus Photography for Traditional Grading in AMD 
 
Use of color fundus photography has been the standard and most effective 
imaging tool employed by retinal specialists in the diagnosis and manual grading of 
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intermediate AMD to date90. Many grading systems have been presented that use 
fundus photography for diagnosis, but one of the most common, and the one employed 
by the AREDS study, is the Wisconsin Age-related Maculopathy Grading System91. In 
this system, a grid consisting of three circles measuring 500um, 1500um, and 3000um in 
radius, and four radial lines that are concentric with the center of the macula, is placed 
on a plastic sheet and superimposed on the fundus image (Figure 2.1). In addition to the 
placement of this grid on the center of the macula, the retinal specialist uses a reference 
set of open circles corresponding to different sized area measurements. A trained grader 
or retinal specialist uses these circles to sum the total surface area covered by the 
feature to then assign a grade (Figure 2.1). 
On the Wisconsin Scale, drusen are measured and categorized into small, 
intermediate, and large. Small drusen are those that have a diameter less than 63um, 
medium sized drusen have a diameter in the range of 63um to 125um, and large drusen 
are those that are larger than 125um.  Intermediate AMD is characterized by the 
presence of a substantial number of medium sized drusen or by the presence of one 






Figure 2.1: Age-related Maculopathy grading grid with reference circles. 
Within the grid the three circles with 4 radial lines originating from the center represent radii of 500 um, 1500um, 
and 3000um. On the right are the typical set of open circles of varying sizes for estimating the size of AMD related 
abnormalities including GA and drusen. Circle C-0 represents 63um in diameter, C-1 equals 125um in diameter, 
c-2 equals 250 um, I-1 equals 175um, I-2 equals 350um, O-1 equals 332 um, and O-2 equals 644 um. Adopted 
from Klein et. al91. 
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Figure 2.2: A-D: Drusen of Varying Severity and Type 
In this figure we observe varying sizes and number of drusen that present themselves within 
the retina. The images are to highlight the tedious and difficult process that is required to 
accurately quantify drusen.  Figure A. We observe an abundance of small to intermediate 
hard druse. Figure B-C. We observe small, intermediate, and large hard and soft drusen. 
Figure D. We observe large soft confluent drusen.  
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Cohort Grade Classification and Eligibility Requirements 
 
AREDS 
Categorization of AREDS subjects into AMD severity groups for the clinical trial 
was based upon a one through four-grade classification scheme. A grade of one 
corresponded to both eyes of a subject having at most small non-extensive drusen and 
no pigment abnormalities. Subjects in this grade must also have had a corrected visual 
acuity score greater than 74 letters. A grade of two corresponded to at least one of the 
subject’s eye having either extensive small drusen, multiple intermediate drusen, or 
pigment abnormalities that have been known to be associated with AMD. These subjects 
must not have had large drusen or advanced AMD in either eye or a visual acuity score 
less than 73 letters. 
Subjects with a grade of three are broken down into two (A and B) subcategories. 
Subjects with a grade of 3A have at least one eye with one or more of the following; one 
or more large drusen, intermediate drusen covering at least that of circle I-2 in the 
presence of soft drusen, intermediate drusen covering the area at least of circle O-2 if 
soft indistinct drusen are not present. These subjects also may have had geographic 
atrophy if it was not observed within the center of the macula. In addition, subjects with a 
grade of three must not have had advanced AMD in either eye or a visual acuity score of 
73 or less letters if associated with AMD. Subjects in subcategory 3B met the 
requirements for 3A in one eye and the fellow eye has a visual acuity score less than 73 
letters that is not associated with AMD.  
Subjects with a grade of four could be broken down into two subcategories, 4A 
and 4B. Subjects with a grade of 4A are those that showed the presence of advanced 
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AMD in one eye but not the other, and a visual acuity score that was or was not less 
than 73 letters or less. Subjects with a grade of 4B were those that had a visual acuity 
score less than 74 letters and no presence of advanced AMD. The fellow eye for this 
subject must also have had a visual acuity score greater than 74 and no advanced AMD. 
A brief summary of the AREDS classification scheme is given in Table 2.1. 
To be eligible for the phase two clinical trial, the following visual acuity 
requirements must have been met per subject. Subjects given a grade of one or two 
must have had a visual acuity greater than 74 letters in each eye, subjects assigned a 
AMD grade of three must have had a visual acuity of 74 or more in at least one eye with 
large drusen or geographic atrophy not included in the central macula region. Subjects 
given a grade of four in one eye must have had a visual acuity score greater than 74 
letters in the fellow eye if advanced AMD was not present. Subjects given a grade of four 











Table 2.1: AREDS AMD Classification Scheme. 
Table taken from The Age-related Eye Disease Study Group et. al 199992 
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The age requirements for subjects to be included in phase two were that subjects 
with an AMD category of one or two needed to be of age 60 through 80 at the time of 
qualifying visit, and subjects with a grade of three or four needed to range from 55 
through 80 at the qualifying visit. Subjects that were over the age of 78 at the time of 
registration for phase one were age eligible for the phase two qualifying visit regardless 
of AMD severity grade. 
In addition to the age and visual acuity requirements, subjects were also 
screened for the presence of a history of retinal abnormalities other than AMD. 
Abnormalities warranting exclusion included central serous choroidopathy, optic atrophy, 
surface wrinkling retinopathy, retinal pigmentary changes that are not specific to AMD, 
macular hole, retinal vein occlusion, or general ocular diseases that could potentially 
impact the assessment of AMD or cataracts. In addition, subjects that showed the 
presence of diabetic retinopathy were excluded. To reduce the enrichment of subject 
eyes with glaucoma, subjects that had an intraocular pressure of greater than 26mm Hg 
or a medical history eluding to the potential presence of glaucoma were given a visual 
field exam to look for the presence of glaucomatous visual field defects. Subject eyes 
presenting with any of these glaucoma related abnormalities were excluded. 
Surgical based exclusions included subjects with a history of laser 
photocoagulation for peripapillary CNV or for AMD in the eye receiving treatment. 
Subjects who received cataract surgery within 6 months of the phase 2 qualifying visit 
were also excluded for that eye.  
CWRU/HIHG 
Information about the inclusion criteria and ascertainment for the CRWU/ HIHG 
cohort can be found in chapter III. The exclusion criterion for this cohort included any 
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case that has had a history of retinal surgery, laser photocoagulation, glaucoma, diabetic 
retinopathy, or any other eye-related disease. 
The grading scale used by the CWRU and HIHG for the diagnosis of AMD is a 
derivation of the classification scheme used by AREDS and is described in Table 2.2. 
The major modification of the AREDS scale is the addition of a fifth category to 
differentiate advanced AMD into geographic atrophy (grade four) and choroidal 
neovascularization (grade five). As this is a step scale, subjects that present with both 
geographic atrophy and neovascularization are categorized as grade five.  
Table 2.2: CWRU and HIHG Grading Scale 
Table taken from Spencer et. al 200793 
 
Selection of Samples for Drusen Analysis 
 Information about the selection criteria of subjects from both the AREDS and 
CWRU cohorts can be found in chapter III. 
 
35 
Image Quality Control 
 
 To accurately quantify drusen load, it is necessary to have images of sufficient 
quality to detect drusen of varying size (small, medium, large) and type (hard and soft). 
As such, prior to analysis of drusen progression, we employed both computational 
assessed quality score measures and subjective quality score measures to both the 
AREDS and CWRU/HIHG datasets. It is important to note that capturing of fundus 
photos by the AREDS clinical centers was completed in a non-digital format. The 
cameras employed at these centers were the Zeiss FF series of cameras, which took 
analogue fundus photographs using transparency type film. Clinical centers were 
approved to use either Kodachrome or Ektachrome film with this camera type.  
To reduce variability in images over time, centers were required to only use one 
film type over the course of the entire study, although each center was free to choose 
which of these films to use. Within the variables given by AREDS, there is no note on 
which film type was selected at each reading center and thus cannot be assessed as a 
potential bias in drusen quantification.  Subjective information about photographic quality 
was completed as part of AREDS; this information was not made available to the public 
on a per image basis. It must also be noted that quality assessment by the AREDS 
grading center was completed on the native non-digital images and not the digitized 
images. Thus, although digitization of fundus photographs on a whole may not lead to 
major artifactual differences between native image and the digitized images, we are 
aware that we are analyzing copies that are further processed into JPGs by AREDS.  
 In contrast to the AREDS fundus photographs captured using transparency film, 
fundus photographs captured as part of the CWRU and HIHG dataset were taken 
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digitally using either a Zeiss 450 (Carl Zeiss, Jena, Germany) camera at the Vanderbilt 
Eye Institute, or a Topcon TRC 50IX camera (Topcon 50IA, Tokyo, Japan) at the 
Bascom Palmer Eye Institute.  
As part of the quality control process, we performed a first pass removal of poor 
quality images based on manual image inspection. Major criteria for image removal 
included blurriness to a point where small drusen could not be delineated, improper 
distance of camera from the eye, lateral misalignment of the camera, presence of the 
grading grid on the image, major variation in contrast across the photograph, images 
missing the full macular field,  and absence of the optic nerve as this is used in 
alignment of the grading grid. Examples of these major quality issues are presented in 
Figure 2.3 A-H. Images from the CRWRU/HIHG dataset were screened prior to the 
onset of this study and were not confounded by these artifacts.  
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Figure 2.3 A-H: Example of Major Artifacts Present in AREDS Photographs 
Figure A. Large color variation across fundus field. Figure B. Lateral misalignment of camera.  





Figure 2.3 A-H: Example of Major Artifacts Present in AREDS Photographs 
Figure E. Image too blurry to delineate drusen. Figure F. Camera too close to eye Figure G. Camera too 




After removal of images based on gross artifacts, we performed a computational 
assessment of image quality using a retinal workstation package developed at Radboud 
University Medical Center94.  Quality assessment with this package is calculated as a 
continuous measure from zero, being very poor, to a score of one being very good. 
Metrics involved in calculating the quality score include the level of blurriness, contrast in 
the image, level of brightness, and ability to delineate anatomical features such as the 
optic nerve and blood vessels surrounding the macula. Results from the quality 
assessment differed greatly between the CWRU/HIHG dataset and the AREDS dataset. 
When we examined the distribution of quality scores in the Case/Western HIHG dataset, 
we see a bimodal distribution with most images being of high quality according to the 
quality assessment algorithm (Figure 2.4 A). When we examine the quality distribution of 
the AREDS data we again see a bimodal distribution, although in these data most 
images fall into the low quality range (Figure 2.4 B). 
 Visual inspection of images given a low quality score by the algorithm did not 
generalize well to manual image inspection as we observed many cases of images 
being given a low quality score in the AREDS dataset but being of good quality when 
visualized manually. When we group quality scores into categories of less than 0.25 and 
greater than 0.75, as this is where most of the images fall in the quality distribution, we 
do not observe a significant difference in quality score versus drusen area based upon a 
Wilcoxon Rank Sum test (p-value = 0.06;Figure 2.5). This led us to conclude that quality 
score data given by the retina workstation package was not having an effect on drusen 
area quantification. Based on these qualitative and quantitative results the quality score 
did not appear to have value and was not used or investigated further. 
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Figure 2.4 A-B: Quality Distribution of CWRU/HIHG and AREDS Images 
Figure A. CWRU/HIHG Quality Distribution.
 
Figure 2.4 A-B: Quality Distribution of CWRU/HIHG and AREDS Images 
Figure B. AREDS quality distribution.  
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Figure 2.5: Effect of Quality Score on Drusen Calls  
Boxplot examining differences in drusen area when stratifying images by low quality ( < 
0.25) and high quality (> 0.75). 
 
 
Macular Grading Grid Placement and Sizing 
As part of the quantification algorithm, a macular grading grid is automatically 
placed on color fundus photographs to set the region of interest for quantification. Similar 
to manual grading, the digital grading grid is placed on the center of the fovea and the 
outermost grid circle is lined up with the edge of the optic disc. The algorithm 
standardizes the radial distance as 3,000um to translate the pixels of the digital image 
into the metric scale. This relative scaling information was important to our quantitative 
analysis as both the CWRU/HIHG photographs and the AREDS photographs were taken 
using different magnification thresholds. As is presented, AREDS photographs were 30-
degree photos and the CWRU/HIHG photos were 50-degree photos (Figure 2.6 A-B). 
Both types of photographs were centered on the macula. Although different 
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magnifications were employed by the different centers, analysis of drusen is limited to 
areas contained within the grading grid where the fovea is the central reference point. 
The degree of the photo refers to the magnification scale used in the image. 30-degree 
photo is magnified 2.5X larger than life while 50-degree photos translate to 1.5X 
magnification.  
 
Figure 2.6 A-B: Magnification Differences Between 30 and 50 Degree photographs 
Figure A. 30 degree fundus photograph as used by AREDS. B. 50 degree fundus 




As discussed in chapter III, all images were resized to 650 pixels regardless of 
photographic magnification. To adjust for these magnification differences within the 
drusen quantification step, a consensus pixel estimate was determined through 
anatomical measurements of the distance between the center of the fovea and the edge 
of the optic disc. A consensus grid radius of 210 pixels was concluded for the AREDS 
30-degree photos, and a 150-pixel radius was concluded for the CWRU/HIHG 50-degree 
photographs. Through visual examination of the digital grading grid placed on 
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photographs with physical grading grids left attached to AREDS photos, it was 
determined that our consensus 210 pixel radius was exceedingly concordant. Radial 
sizing of the CWRU/HIHG macula grading grid was confirmed by a retinal specialist for 
proper anatomical sizing (M.A.B. at the VEI). 
Drusen Identification Threshold 
 Although the quantification algorithm is an automated process, the user has an 
option of specifying a sensitivity/specificity threshold to determine at what level a drusen 
call should be considered a true call. Drusen that are detected by the algorithm are 
assigned a probability indicating the likelihood that the region contains a true druse. This 
threshold is a sliding scale running from zero, which is high sensitivity, to one, indicating  
high specificity . For our analysis, we chose 0.5 as the threshold based on empirical 
testing by the Diagnostic Imaging and Analysis Group at Radboud University, Nigmegen. 
This threshold was set to include only drusen that were detected with a high probability. 
Examination of CWRU/HIHG Fundus Photograph Replicates 
 Using the parameters discussed in the previous sections, we set out to examine 
the impact of varying image contrast and positioning on drusen quantification. As part of 
the collection of fundus photographs in the CWRU/HIHG dataset, multiple fundus 
photographs were taken of a subject’s eye per visit. Although these images are 
capturing similar amounts of information, we observe differences in image quality 
throughout these replicates. Variation included changes in contrast and brightness, 
slightly different angle of the image with relation to the macula, and subtle variation in 
image focus. In these data, we examined 156 replicates that fit the criteria mentioned 
above. Within these replicates we observe very high replicate correlation, with the major 
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source of variation being due to large changes in focal point and blurriness (Spearman’s 
correlation = 0.97; Figure 2.7) 
Assessing Categorical Versus Quantitative Measures of Drusen Area 
 Following removal of poor quality images and after selection of subjects as 
described in chapter III, we are left with 973 images across 276 subjects in the AREDS 
dataset. Introduced, as tabulated data within AREDS, was a categorized drusen area 
variable (dbGAP variable accession number: phv00054045.v1.p1). As part of this 
variable, drusen area was measured by a retinal specialist and graded on a scale from 
0-7 at each photographed visit. Assignment of drusen area was completed using the 
methods described in the “Use of Color Fundus Photography for Traditional Grading of 
AMD” section. Matching the quantification results with the retinal specialist grades, we 




Figure 2.7: Results of CWRU/HIHG Replication Analysis. 
In this figure, we examine the effect of image variation on quantification results. Major sources of variation included image 
blurriness, focal point, contrast and brightness.  
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Figure 2.8: Quantified Versus Categorized Drusen Area 





Grading of drusen is a long tedious process and the ability to accurately quantify 
this feature manually is difficult due to the complexity in size, shape, and type of drusen 
that present themselves within the macula (Figure 2.2 A-D). Application of manual 
grading to large scale studies can be a daunting task and require a great number of 
resources in the form of human hours devoted by a trained retinal specialist. Inter-grader 
variability also poses an issue due to the sometimes-subjective nature of drusen 
boundaries especially in the face of retinal pigmentary abnormalities and numerous 
small and intermediate drusen. High-throughput automated quantification of drusen 
provide the ability to overcome the issues present with manual grading and to apply 
novel methods to an imaging modality that has been use to collect data for decades. 
Although refinement of these methods is ongoing, we chose to use a previously 
developed algorithm that fully automates the drusen quantification process95. The 
algorithm from which we present our results takes advantage of color fundus 
photographs to extract drusenoid features and calculate total surface area covered by 
drusen within the age-related eye disease study maculopathy grading grid.  
The necessity of having high quality images for quantification is paramount for 
any automated method as this can greatly increase the power of detecting and calling 
true drusen within fundus photographs. Although the AREDS images are described as 
needing to be of sufficient quality to assess the drusen severity spectrum from small to 
large drusen, it quickly became apparent that major quality issues arose upon visual 
inspection of these images.  After removal of fundus photographs with gross artifacts, we 
are left with 973 images in the AREDS dataset that are of a subjectively sufficient quality 
for drusen calling. We computationally assessed image quality with a software package 
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 on the retinal workstation, although the accuracy of the results were not indicative of true 
image quality and did not reflect inaccuracy in drusen calling.  
Analysis of the replicate data shows strong concordance between images within 
the CWRU/HIHG dataset and it appears that the algorithm can perform well in the 
presence of image quality variation. This is a necessity reflective of the repeated 
measure data that we present in the next chapter. 
 Upon examination of the quantitative results compared with the drusen area 
classification scheme developed by AREDS, we observed a steady increase in median 
drusen area when matched to their respective stepwise area classifiers. We do observe 
increasing variation as the drusen area category increases. This may be due in part to 
subjectivity in assignment of area grades by the AREDS retinal specialist since 
assessment is based on a mental calculation of area coverage using a set of referent 
circles of fixed size. 
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 Chapter III 




Age-related macular degeneration (AMD) is the leading cause of blindness in the 
aging population in the developed world. Current prevalence estimates for AMD in the 
United States are 1.52% and 16.39% for ages 70-74 and 8023. By 2020 more than 80 
million people will have some form of AMD96. These prevalence estimates in the elderly 
population will continue to rise drastically as advancements in health care continue to 
increase average life expectancy.  
AMD is a disease that results specifically in central vision loss as it affects the 
macula. Vision loss due to AMD is divided into “wet” and “dry” AMD97. “Wet” 
(neovascular) AMD is the result of new blood vessels arising behind the macula, which 
then begin to leak fluid into the space between the Bruch’s membrane and the RPE 
layer.  Dry AMD is characterized by the presence of a broad range of abnormalities in 
the retinal pigment epithelial layer (RPE) and is considered more common in the overall 
number of AMD cases98. Abnormalities include the presence of drusen, 
hyperpigmentation or hypopigmentation of the RPE, and in the later stages of dry AMD 
progression, geographic atrophy. Although the role that drusen play in the pathogenesis 
of AMD is not currently known, manifestation of these yellow deposits between the RPE 
layer and the Bruch’s membrane is one of the hallmark clinical signs of AMD 
development4. Drusen can be characterized as hard or soft91. Hard drusen are typically 
less than 63 µm in diameter and have discrete borders. Soft drusen are commonly 
greater than 125 µm in diameter and typically have the property of fuzzy indistinct 
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 borders. Many environmental factors have been attributed to AMD risk such as age, 
race, smoking, and cardiovascular risk factors such as obesity and hypertension16, 20, 98-
105. In addition to the factors listed above, genetic studies have successfully identified 
common genetic variation in genes such as CFH, HTRA1/ARMS2, C2/CFB as well as 15 
other loci in sample populations of European ancestry50, 53-57, 61-63, 68, 106-110. 
Of recent interest is the application of these environmental and genetic risk 
factors to create prognostic models of AMD risk111-121. Utilizing models that can predict 
AMD in the clinic may allow for an advantageous contribution to the field of precision 
medicine with respect to AMD treatment. One practical application of identifying the 
underlying risk factors for AMD is building models of disease progression.  These 
models have focused on grouping samples broadly into progressors or non-progressors 
using a dichotomous endpoint, typically defined by measures of visual acuity. This 
approach does not take into account the importance of the rate of progression and uses 
a broad grading system rather than a quantitative measure of disease. By understanding 
how the environmental and genetic components of AMD contribute to the rate of 
progression, we have the potential to understand how to better tailor and administer 
treatment regimens and recommend more appropriate eye evaluation intervals. 
Although significant contributions have been made in the treatment of wet AMD 
with the advent of anti-VEGF injections, there are currently few treatments available for 
dry AMD. Therefore, it is of substantial importance to develop models of AMD 
progression that emphasize characteristics common to dry AMD such as changes in 
drusen load over time. Here we examine the impact of a cumulative genetic risk score 
using 19 common AMD risk variants on drusen progression using data made available 
through the Age-related Eye Disease Study (AREDS), and a combined dataset from 
Case Western Reserve University (CWRU) and the University of Miami Hussman 
Institute for Human Genomics.  
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 Materials and Methods 
 
AREDS Dataset 
AREDS was a major clinical trial that examined risk factors for AMD and 
cataracts, as well as prognostic factors and clinical course of disease. The impact of zinc 
and antioxidants on incidence and progression of AMD was also assessed.  Phenotype 
data tables made available through the database of phenotypes and genotypes (dbGAP) 
on subjects who participated in the AREDS were examined for intermediate AMD 
without the presence of central geographic atrophy or neovascular AMD.  Evaluation of 
the phenotype data was restricted to the 595 subjects that had longitudinal color fundus 
photographs deposited within dbGAP.  Imaging data was available on subjects at 2 year 
intervals with a maximum of 12 years of follow-up. We selected subject eyes and that 
received consecutive diagnoses of intermediate AMD over a course of more than 2 
years based on the AREDS dbGAP phenotype tables. This is represented by individual 
subject eyes receiving an AMD category of 3. An AMD category of 3 is represented by 
the presence of one of the following; one or more large drusen, greater than 20 
averaged size drusen in the presence of soft drusen, 65 average-sized drusen in the 
absence of soft indistinct drusen, or non-central geographic atrophy. Imaging data was 
included up to the progression of intermediate AMD to a severe grade of central 
geographic atrophy or neovascular AMD, and selection of eyes for pulling out imaging 
data was carried out independently per subject eye. Extensive details about the AREDS 
grade categorization, study design, and subject information can be found in AREDS 
report 192. Within dbGAP, 30-degree color fundus photos are available on 3 separate 
fields of the retina. Field 1M is centered on the temporal margin of the optic disc. Field 
2M is centered on the macula, and Field 3M is centered temporal to the macula. For the 
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 relevance of this study, JPG images were downloaded from dbGAP related to field 2M. 
Images were manually and computationally inspected for quality and poor images were 
removed from the dataset. The major features used in determining quality of the images 
Included in this the observation of images with poor focus, images that had the early 
treatment diabetic retinopathy study (ETDRS) grid still attached to the photo, no optic 
nerve-present within the photo, incorrect alignment of the camera leading to images 
containing differential color hues around the periphery of the fundus image, and also 
uneven illumination across the image.   
HIHG Dataset and CWRU dataset 
All cases were ascertained through the retinal clinics at the Vanderbilt Eye 
Institute (VEI) or the Bascom Palmer Eye Institute (BPEI) as part of a longitudinal study 
examining progression and response to treatment of severe AMD. 50-degree color 
fundus photos were taken at these visits using either a Zeiss 450 (Carl Zeiss, Jena, 
Germany) camera at the VEI, or a Topcon TRC 50IX camera (Topcon 50IA, Tokyo, 
Japan) at BPEI. Participants were graded by a retinal specialist on a 1-5 scale modified 
from AREDS at each visit with visit intervals ranging from 1, 4, 6,8,10, and 12 months122, 
123 . A grade of 1 or 2 was assigned to controls, grade 3 represented early/intermediate 
AMD, and grades 4 and 5 represented late AMD (geographic atrophy and choroidal 
neovascularization, respectively). Subjects were retrospectively examined for visits with 
color fundus photos graded as a 3 on the modified AREDS grading scale. Subjects that 
presented with continuous intermediate AMD for 1 year or more in the absence of 
geographic atrophy or neovascular-AMD had their imaging data examined.  A minimum 
interval of 6 months between images was used in the CWRU/HIHG dataset92, 122, 123. In 
the situation that image intervals were less than 6 months apart, the higher quality image 
was selected from the range while still maintaining a 6 month separation between visits. 
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 Drusen Quantification  
Drusen quantification was completed using a previously developed automated 
drusen detection algorithm. Details about the detection algorithm are defined elsewhere 
but briefly described here95. Images are resized to a radius of 650 pixels for the non-
black region of the image to obtain a standard resolution across all images. Anatomical 
structures are detected including the optic disc, fovea, vessels and image quality 
assessment for calculation of features for drusen detection. Drusen candidate pixels are 
extracted using a pixel classification algorithm. Drusen candidate regions are segmented 
using dynamic programming and drusen candidates are classified as being true druse 
using a large set of features including contrast and intensity changes within the image. 
Quantification is completed based on a threshold drusen probability map which is used 
to generate a binary drusen map to calculate drusen area. An ETDRS grid normalized 
as a 3000 µm radius from the fovea to the edge of the optic disc for each image is 
automatically placed. Although this is a fully automated process, each image was 
manually reviewed for proper placement of the ETDRS grid. We found that our digital 
ROI matched precisely with ETDRS grids left on digitized AREDS photos. Drusen 
surface area was quantified in each image’s ROI as millimeters2 and used for 
downstream analyses. 
Genotyping 
Genotyping data for both the CWRU/HIHG and AREDS datasets were made 
available through the International AMD Genomics Consortium (IAMDGC) (Fritsche et. 
al.  2015, In Review) and through permission of Dr. Emily Chew at the National Eye 
Institute (NEI). Details about the quality control procedures carried out by the IAMDGC 
can be found elsewhere (Fritsche et. al.  2015, In Review). Nineteen common variants 
previously associated with AMD were selected either through direct genotyping on the 
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 IAMDGC exome chip array or through surrogate SNPs found to be in high LD (r2>0.8) 
with these variants if not directly genotyped.   
Drusen Progression Rate Estimation 
 Since our data are represented by multiple visits per subject and drusen 
measurements in either one or two eyes, we employed a linear mixed effects model 
(LMEM) to estimate changes in drusen area over time using a similar modelling scheme 
to what has been presented for estimating GA progression rates112. Modeling of drusen 
progression rates was carried out using the R software package (R version 3.02) and the 
R-library “Linear mixed-effects models using Eigen and S4” (lme4, version 1.1-7). In 
brief, LMEM allows for an estimation of a population mean regression line known as a 
fixed-effect and deviations from that mean slope and intercept through estimation of 
random-effects. This multi-level modeling also allows for incorporation of information on 
both eyes for a subject if available, giving us a single measure of drusen growth. P-
values were generated with the R-package “Tests in Linear Effects Models” 
(LmerTest,version 2.0-20) using Satterhwaite’s approximations. 
Analysis of Drusen Progression against Demographic, Endpoint Severity, and 
Treatment category 
To examine the role of sex, smoking, AREDS treatment category, and age, the 
following statistical analysis plan was carried out. We first examined the impact of 
smoking, age, and treatment category independently within the mixed model of drusen 
progression to see the necessity of including these factors as covariates for the genetic 
analysis. Age was examined as a measure of correlation with drusen progression by 
way of a Pearson’s correlation coefficient. Sex and smoking were examined as 
interaction terms within independent mixed-models. To understand the potential role of 
drusen growth on the progression of AMD from intermediate to neovascular AMD or 
geographic atrophy, study subject’s endpoint severity was categorized into either 
55 
 “drusen only”, “geographic atrophy”, or “neovascular AMD”. These severity categories 
were determined by using AREDS severity score information made available through the 
AREDS dbGAP data tables. Subjects were categorized based upon first instance of 
severe progression. In the case that subjects did not progress to geographic or 
neovascular AMD by the end of the full AREDS clinical trial and natural history study, 
subjects were categorized as having “drusen only”. Endpoint severity categories were 
coded as dummy variables and the “drusen only” category was set as referent within the 
model. 
Cumulative Genetic Risk Score Analysis and Independent SNP Tests 
 For our primary analysis, the 19 variants or their respective surrogate SNPs 
were incorporated into a cumulative genetic risk score representing the major common 
variation contributing to AMD genetic risk124. Each variant was weighted by the effect 
size given by the AMD Gene consortium and multiplied by the number of risk alleles 
present at that locus. More details about the weighting scheme and application of this 
risk score can be found elsewhere122, 124, 125. To examine the effect of the genetic risk 
score on drusen progression, a Pearson’s correlation coefficient was calculated using 
each subject’s progression slope versus their cumulative genetic risk score. Examination 
of each of the common variants role in drusen progression was carried out 
independently by the inclusion of the number of risk alleles at each loci coded in an 
additive manner, and included as an interaction term within the mixed models.   
Pathway Analysis 
To examine the role of drusen progression in a pathway based analysis, a 
quantitative genome-wide association analysis was carried out in Plink using drusen 
progression rates as an outcome variable for the 274 AREDS subjects against the 
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 genome-wide SNP data present on the exome-chip array126. A minor-allele frequency 
cutoff of 0.05 based on the 274 AREDS subject sample was used. Pathway analysis 
was performed on the results of the single variant tests using the Pathway Analysis by 
Randomization Incorporating Structure (PARIS) algorithm, and restricted to the Kyoto 






Within the AREDS dataset, 246 of the 595 subjects available through dbGAP had 
either a baseline grade of intermediate drusen or progressed to intermediate drusen and 
had continuous visits of intermediate AMD for at least 2 years during the measured 
follow up (Table 3.1). In the CWRU/HIHG dataset, 75 subjects of the 500 subjects 
examined met the selection criteria as the independent dataset (Table 3.1). Analysis in 
the AREDS and CWRU/HIHHG datasets was restricted to the first 6.5 years of follow up 
and represents the median duration of the AREDS clinical trial. Although imaging data 
was available for the natural history portion of the AREDS study, a large proportion of 
the samples we selected for the study had progressed to severe AMD after the 6.5 year 
time point and thus did not have usable longitudinal data at that stage. The median 
number of visits with quantifiable images including baseline was 3.4 with a total of 973 
images being used in the AREDS analysis and 75 subjects with a total of 272 images 
and a median number of visits of 3 for the CWRU/HIHG dataset.  Of the 246 subjects 
AREDS subjects selected, 88 subjects had imaging data that fit our criteria in both eyes, 
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 and 158 subjects had imaging data available for one eye. In the CWRU/HIHG dataset 
we observed 24 subjects with bilateral intermediate AMD. We observed high correlation 
in drusen area  
Table 3.1: Study Population Demographics 
“AREDS Study” represents the entire sample set available in dbGAP with and without 
longitudinal imaging data. “AREDS Sampled” represents the 246 samples that had 
longitudinal data and met our filtering criteria. “CWRU / Miami” represents subjects with 
longitudinal imaging and genetic data available in this study population 
Variable AREDS Study 
(N = 4757) 
AREDS Sampled 
(N = 246) 
CWRU / HIHG 
(N=75)  
Age at Exam (Years)       
Median 69.4 69.3 73.5 
Gender, n (%)       
Male 2098 (44.1) 101 (41.1) 50 (66.7) 
Female 2659 (55.9) 145 (58.9) 25 (33.3) 
Ever Smoked, n (%)       
Yes 2650 (55.7) 151 ( 61.4) 26 (60.4) 
No 2107 (44.3) 95 (38.6) 17 (39.6) 
 
between eyes of subjects at baseline (rho = 0.857, p-value <2.20*10^-6; Figure 3.1) in 
bilateral intermediate AMD subjects. Correlation of bilateral progression was also 
significant (rho = 0.300, p-value = 0.004; Figure 3.2) within these 88 subjects. We 
observed significantly higher drusen area in subjects with both eyes present in the study 
versus subjects that had just one eye in our study (p-value = 0.024). We do not observe 
a significant association of drusen progression with sex, age at first exam, smoking 





 Figure 3.1: Correlation at Baseline between Eyes  
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 Genetic Data 
We observe correlation with drusen baseline area and the cumulative genetic risk 
score (rho = 0.175, p-value = 0.006; Figure 3.3). We do not observe significant 
correlation between the 19 variant cumulative genetic risk score and drusen progression 
(rho = 0.039; p-value = 0.543; Figure 3.4). We do not observe a significant association 
with the top four highly associated variants reported by the IAMDGC and drusen 
progression (Figure 3.5 and Table 3.2).  In single marker tests of the SNPs that make up 
the risk score, we observe a nominally significant association with rs943080 in VEGFA 
(p-value = 0.0281; Appendix A), this does not pass multiple testing correction. Pathway 
analysis was performed using the results of the quantitative GWAS based on the 
IAMDGC exome-chip array. In total, p-values were generated for 252,376 variants that 
met the minor allele-frequency cutoff of 0.05 and a genotyping efficiency of 95% 
(Appendix B). Of the 199 pathways that were interrogated as part of the KEGG 
database, the most highly associated pathway that passed Bonferonni correction was 




 Figure 3.3: Correlation of Drusen Area at Baseline and Risk Score 
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 Figure 3.4: Correlation of Drusen Progression and Risk Score 
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 Table 3.2: Results of Single-Variant Association Analysis with Progression 
 
  AREDS CWRU / HIHG 
Variant Estimate SE P-value Estimate SE P-value 
rs3812111_T_COL10A1 -0.01 0.007 0.193 -0.001 0.02 0.954 
rs6795735_T_ADAMTS9.MIR548A2 0.003 0.008 0.681 -0.006 0.021 0.778 
rs4698775_G_CFI 0.008 0.007 0.293 -0.019 0.018 0.308 
rs9542236_C_B3GALTL -0.012 0.007 0.099 0.023 0.023 0.314 
rs920915_C_LIPC -0.001 0.007 0.932 0.025 0.023 0.283 
rs8017304_A_RAD51B -0.015 0.008 0.06 0.024 0.02 0.246 
rs943080_T_VEGFA 0.016 0.007 0.028 0.01 0.018 0.581 
rs8135665_T_SLC16A8 -0.008 0.009 0.383 0.023 0.024 0.347 
rs334353_T_TGFBR1 -0.013 0.009 0.126 0.031 0.023 0.198 
rs79037040_T_tnfrsf10b_surrogate 0.009 0.007 0.216 0.021 0.024 0.375 
rs115515129_G_ddr_surrogate -0.0001 0.009 0.988 0.04 0.025 0.111 
rs13081855_T_COL8A1.FILIP1L -0.009 0.012 0.453 -0.015 0.043 0.736 
rs1864163_G_CETP 0.006 0.009 0.46 -0.009 0.026 0.731 
rs4420638_A_APOE -0.006 0.01 0.579 -0.047 0.033 0.155 
rs2230199_G_C3 0.003 0.008 0.728 -0.03 0.02 0.143 
rs5754227_T_timp_surrogate 0.018 0.011 0.106 0.026 0.03 0.4 
rs116503776_G_c2_cfb_surrogate -0.005 0.014 0.712 -0.026 0.043 0.553 
rs10737680_A_CFH 0.013 0.009 0.156 -0.015 0.026 0.556 
rs10490924_T_ARMS2 -0.002 0.008 0.781 0.005 0.019 0.809 
 
64 
 Figure 3.5 A-E: Drusen Area Progression by Genotype 
Figure A. ARMS2 Risk Alleles in the AREDS dataset 
 
 
Figure 3.5 A-E: Drusen Area Progression by Genotype 




 Figure 3.5 A-E: Drusen Area Progression by Genotype 
Figure C. C2/CFB Risk Alleles in the AREDS dataset 
 
Figure 3.5 A-E: Drusen Area Progression by Genotype 
Figure D. C3 Risk Alleles in the AREDS dataset 
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 Figure 3.5 A-E: Drusen Area Progression by Genotype 






AMD is a complex disease containing phenotypic heterogeneity with respect to 
the combinatorial presence of drusen, geographic atrophy, and neovascular AMD. In this 
analysis we examined the potential role of the 19 major genetic risk loci to drusen growth 
during the intermediate stages of the disease in the absence of neovascular AMD and 
geographic atrophy. Since the bulk of studies examining drusen have treated this 
phenotype as a binary response, we wanted to potentially refine the precision of 
examining this phenotype by treating it as a quantitative variable through a previously 
established drusen quantification algorithm that takes advantage of color fundus 
photos95.  
In a recent study performed by the AREDS study research group it was found 
that increasing drusen severity at baseline was a significant predictor for progressing to 
geographic atrophy and neovascular AMD92. We observed similar findings when 
examining drusen at baseline as a continuous variable and the 10 year endpoint severity 
outcome of study participants that met our inclusion criteria. Study eyes that maintained 
intermediate AMD throughout the course of the AREDS study had significantly lower 
average total drusen area compared to subjects that had baseline intermediate and 
progressed to geographic atrophy and neovascular AMD. This observation is present in 
the CWRU/HIHG dataset as well. We did not observe significant differences in rate of 
drusen progression within the first 6.5 years of follow up and the 10 year outcome of 
severity.  
Although smoking and age are major risk factors for AMD they do not appear to 
have a major effect on drusen within our dataset. It is important to note that we do not 
differentiate subjects based on whether they were current smokers during the time of the 
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 AREDS study or by pack years of smoking exposure. Age was limited to those aged 55 
years or older at baseline and subjects that already have presence of intermediate AMD. 
We observe a highly significant correlation of drusen area within subjects that present 
with bilateral intermediate AMD (rho = 0.847, p-value < 0.0001). This observation may 
be inflated as we are not including subject eyes that have either severe AMD in the 
fellow eye, or not enough medium to large drusen to be classified as intermediate AMD. 
These correlation findings have also been observed by other groups looking at bilateral 
drusen using optical coherence tomography and thus our results are consistent with 
these previous findings128. When examining correlation in bilateral drusen progression 
within these same subjects, we see significant although reduced correlation (rho = 
0.300, p-value = 0.004). 
Genotype data were chosen based on previous work carried out by the 
AMDGENE consortium that identified 19 major common AMD risk variants that may 
explain up to 65% of the variation seen in AMD124. For our primary genetic analysis, 
these 19 variants were aggregated into a cumulative genetic score to examine its impact 
on drusen at baseline and progression. The risk score analysis revealed significant 
correlation with drusen area at baseline (rho = 0.17, p-value = 0.005) and no correlation 
with drusen progression (rho = 0.039; p-value = 0.543). It is important to note that SNP 
weights assigned to the variants used in the risk score are based on the AMDGENE 
consortium analysis that performed a cross-sectional analysis of risk and as such these 
weights may not be representative of their role in progression.  In a secondary analysis 
we attempted to dissect the role of these variants to drusen progression but did not find 
any single variant that substantially contributes to drusen progression. 
As we are presenting a case-only analysis in 2 smaller datasets, power is a 
significant concern.  Post-hoc power calculations show that we had had 80% power to 
detect an effect size of 0.0196mm2/year when correcting for the 4 major loci. We had 
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 56% power to detect a significant association in the cumulative genetic risk score 
progression analysis based on the estimated effect size and sample size in the AREDS 
dataset. Power in the independent association analysis for the big four variants within 
CFH, ARMS2/HTRA1, C2/CFB, and C3 was also severely limited at under 10% after 
multiple test correction.  Variant rs943080, which is near VEGFA, was the only variant 
nominally associated with drusen progression out of 19 loci that make up the cumulative 
genetic risk score. Power to detect an association in this variant was 37% based on 19 
test corrections.  This variant did not replicate within our Miami / CRWU dataset although 
the sample size and power of this dataset was even further limited. 
A second exploratory approach is to aggregate potential effects not using a 
genetic risk score, but on functional relatedness. We performed a pathway based 
analysis to see whether any functional pathways within the KEGG database were 
enriched for drusen progression. The top pathway that was enriched was the cell 
adhesion molecule pathway (KEGG database id: hsa04514; Appendix C). We identified 
three genes driving the signal. These genes were neurofascin (NFASC) on chromosome 
1 (p-value = 0.0004), CD226 molecule (CD226) on chromosome 18 (p < 0.0002), and 
neurexin 1 (NRXN1) on chromosome 2 (p-value = 0.0006). The statistical significance of 
these genes was confirmed using the gene enrichment program “Versatile Gene-based 
Association Study” (VEGAS). Results from the VEGAS analysis can be found in 
appendix D. Molecules in this pathway play a role in a wide array of functions including 
inflammation and immune response. Previous work has shown that inflammation 
between the RPE layer and the Bruch’s membrane may play a role in AMD associated 
drusen formation mainly through cellular debris trapped between these layers3, 129.  In 
another study examining the impact of cell adhesion molecules on AMD, it was shown 
that soluble vascular cell adhesion molecule 1 associates with increased incidence of 
early AMD130. These findings highlight that although the major 19 risk loci may not 
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 contribute significantly to drusen progression within our study, there may be other 
variants of functional importance directly or indirectly impacting drusen growth during the 
intermediate stage of disease. 
One of the major limitations that we found during the course of this study was the 
quality of images available from the AREDS dbGAP dataset. AREDS images made 
available in dbGAP are not original images, but digitized copies of slide transparency 
film. Photographs taken at the VEI and BPEI were native digital images. All images from 
both the native digital images obtained in the CWRU/HIHG dataset and the digitized 
photos from AREDS were assessed for quality using an automated algorithm that 
assigns a quantitative quality score to the image based on a number of metrics including 
blurriness, contrast in the image, and ability to delineate blood vessels surrounding the 
macular. A major proportion of the AREDS images were considered poor by this 
algorithm, which did not necessarily reflect the qualitative assessment of the images by 
a retinal specialist. Assessing the quality of the directly digitized images from the 
Miami/Case Western data we observed most images falling into the high quality range 
both quantitatively and qualitatively. It may be that the process of taking the fundus 
slides from transparent film in the AREDS dataset to digital copies affects the ability for 
accurate automatic quality assessment of the images. We must also be aware that the 
overall low quality of the AREDS images when examined in a longitudinal format may be 
introducing too much variation across time-points to accurately measure drusen 
progression. This may be somewhat reflected between differences in correlation 
between intra-subject drusen at baseline and bilateral drusen progression, where we see 
a highly correlated baseline measurement, but reduced bilateral progression correlation. 
Thus if the effect sizes of the major common risk loci are more modest for drusen growth 
, we may not be able to overcome the signal to noise ratio introduced by image quality. 
Although the CWRU/HIHG images were of superior quality, the size of the dataset 
71 
 limited our power to detect a true association with drusen at baseline or drusen 
progression. Although we were able to retrospectively collect previous retinal visits on 
subjects within the progression and treatment study, the major ascertainment criteria for 
these participants was severe AMD, thus longitudinal data was sparse prior to the 
presence of reduction in visual acuity.  
It is important to note that no study to date has been published that details the 
role of the major AMD risk loci in quantitative drusen progression, and thus is an 
important step in understanding the role of drusen etiology in AMD genetics.  
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 Chapter IV 
 
RARE COMPLEMENT FACTOR H VARIANT ASSOCIATED WITH AGE-RELATED 




Age-related macular degeneration (AMD) is the leading cause of blindness in 
individuals over the age of 65 in the developed world23, 131. AMD is a progressive 
neurodegenerative disease that results in central vision loss. Vision loss caused by AMD 
is generally divided into two categories. Non-neovascular or “dry” AMD is characterized 
by the presence of a broad range of abnormalities in the retinal pigment epithelial layer 
(RPE). Clinical characteristics include the presence of drusen, hyperpigmentation or 
hypopigmentation of the RPE, and, in later stages, geographic atrophy, which results 
from retinal pigment epithelial (RPE) layer cell death132. Neovascular or “wet” AMD 
occurs when new blood vessels form behind the macula, leaking fluid into the space 
separating the Bruch’s membrane and the RPE layer132.  
AMD risk has been attributed to many lifestyle influences such as age, race, 
smoking, and cardiovascular risk factors including obesity and hypertension20, 98, 103, 107, 
133. Genetic studies have identified common variants with strong associations in CFH 
and ARMS2/HTRA1, as well as multiple loci of smaller effect, in populations of European 
1 Adapted from: Joshua D. Hoffman, Jessica N. Cooke Bailey, Laura D’Aoust, William Cade, Juan Ayala-Haedo, Denise 
Fuzzell, Renee Laux, Larry D. Adams, Lori Reinhart-Mercer, Laura Caywood, Patrice Whitehead-Gay, Anita Agarwal, 
Gaofeng Wang,  William K. Scott, Margaret A. Pericak-Vance, Jonathan L. Haines. Investigative Ophthalmology & Visual 
Science. 2014 June 6; 55(7):4455-60.  
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 descent46, 50, 55, 57, 62, 134. A recent meta-analysis completed by the AMDGene Consortium 
showed that the most strongly associated variants in CFH and ARMS2/HTRA1, in 
combination with 17 other loci that reached genome-wide significance, account for less 
than 65% of the total genetic contribution to AMD135. While this shows success in 
common variant analysis, there is still a gap in the total genetic variation yet to be 
explained by this complex disease. Some of this missing heritability is thought to lie 
within rare variants of large effect81, 136-138. To address the deficit in knowledge of rare 
variants influencing AMD, we exome sequenced individual members of a nuclear family 
who represent a subset of the Ohio-Indiana Amish population. 
The Amish are a genetically and culturally isolated founder population descended 
from Swiss and German Anabaptists who emigrated from Western Europe to North 
America in the 1700s and 1800s139. Individuals of the Amish community typically marry 
within the faith and observe a strict lifestyle, resulting in a community that is more 
genetically and environmentally homogeneous than the surrounding population. Due to 
the intermarriage within the community and relatively recent founder event, this 
population may also be enriched for some rare variations. These factors, in addition to 
an extensive family record available through the Anabaptist Genealogy Database 
(AGDB), make the Amish a unique and valued population for genetic studies85, 140, 141.   
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 Materials and Methods 
 
Subjects:  
Amish subjects were selected from the Collaborative Aging and Memory Project 
(CAMP), an ongoing sample collection of Amish individuals living in the United States in 
Ohio and Indiana, described elsewhere87, 142. Construction and maintenance of the 
Anabaptist Genealogy Database (AGDB) is covered under an IRB-approved protocol at 
the National Institutes of Health (Dr. Leslie Biesecker, Principal Investigator). AMD 
affection status was assigned based on self-report questionnaire response where 
subjects were asked if they had ever been diagnosed with AMD by a physician. A subset 
of 73 participants (42 cases, 31 controls) received a follow up clinical exam by a retinal 
specialist. The self-report dataset included 128 individuals with AMD, 728 individuals 
without AMD, and 294 with no self-report information, and all individuals were connected 
into a single 13-generation pedigree based on an “all common paths” query of the AGDB 
using PedHunter 2.0 software and shown in figure 4.1143.  
Non-Amish subjects were ascertained from the Duke University Eye Center 
(DUEC), the Vanderbilt Eye Institute (VEI), and the Bascom Palmer Eye Institute (BPEI) 
at the University of Miami Miller School Of Medicine. Participants were examined by a 
retinal specialist and graded on a severity scale derived from the Age-Related Eye 
Disease Study (AREDS), described elsewhere40, 122. Grades were given on a scale of 1-
5 where grades 1 and 2 were assigned to controls, grade 3 represented early AMD, and 
grades 4 and 5 represented late AMD (geographic atrophy and choroidal 
neovascularization, respectively). Amish participants who received a clinical diagnosis 
were graded using the same criteria. The final non-Amish dataset contained 1,732 
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 cases, 943 controls, and 310 unknown samples. Demographic information for both the 
Amish and non-Amish datasets is depicted in table 4.1. 
 
Table 4.1:Demographics for Amish and Non-Amish Datasets 
 
As part of ongoing AMD family studies, a single nuclear Amish family (family 1) 
with multiple individuals affected with AMD (three of eight siblings affected) was noted. 
Affected members lacked risk alleles at the Y402H locus in CFH and at the A69S locus 
in ARMS2. The three affected siblings (a-78, a-79, a-80) (Figure 4.2) were clinically 
evaluated to confirm disease status. The other siblings were not available for clinical 
examination at the time of exome sequencing, although a self-report diagnosis was 
completed.  Subject a-78 was diagnosed with bilateral choroidal neovascularization 
(Grade 5); subjects a-79 and a-80 were diagnosed with large drusen in both eyes 
(Grade 3). Details of clinical grades and age at time of diagnosis for the ascertained 
nuclear family are included in figure 4.2. All procedures followed the tenets of the 
Declaration of Helsinki and were approved by the institutional review boards of the 
University of Miami Miller School of Medicine and Vanderbilt University. Informed 
consent was obtained from all research subjects involved in this study.   
  
76 
 Cumulative Genetic Risk Score Analysis:  
Genetic risk scores were calculated using the 19 variants and their effect sizes 
reported by the AMDGene consortium’s meta-analysis15. Genotyping was performed 
using the Sequenom MassARRAY genotyping platform (Sequenom, San Diego, USA). 
Subjects that presented with missing genotypes at any of the 19 loci were excluded from 
the analysis. Each variant was weighted and multiplied by the number of risk alleles 
present at each locus, where the SNP weight (w) is equal to the individual SNP beta-
estimate divided by the sum of the beta-estimates across all 19 loci (formula 1). Risk 
scores from each of the 19 loci were summed to give the cumulative genetic risk score 
per person.  
77 





 Figure 4.2: Pedigree of nuclear family chosen for exome sequencing.  
*Clinical diagnoses were available for a-78, a-79, and a-80 at time of exome sequencing. Grading was carried out according to the 
modified AREDS scale. 
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 Two-sided t-tests assuming unequal variance were calculated in the Amish case-control 
group and Non-Amish versus Amish case group. 
(1) Cumulative genetic risk score = w1 Genotype1 + w2 Genotype2 + … + w19 Genotype19 
Exome Sequencing:  
DNA for all samples was extracted from whole blood by the Vanderbilt University 
DNA Resources core and the John P. Hussman Institute of Human Genomics (HIHG) at 
the University Of Miami Miller School Of Medicine using PureGene DNA extraction 
methods (Gentra Systems, Minneapolis, MN). The three clinically examined members of 
family 1 were selected for exome sequencing. Exome capture was performed using the 
Agilent SureSelect All Exon kit V. Exon enriched libraries were sequenced on the 
Illumina HiSeq 2000. Sequence capture and high-throughput sequencing were 
completed at the HIHG.  Paired end reads were generated and mapped to the human 
reference genome (version hg19 from UCSC) using Burrows-Wheeler Aligner144.  
Duplicate reads were marked using Picard tools and local realignment around insertions 
and deletions was performed using the Genome Analysis Toolkit (GATK)145. 
Realignment was performed using the base quality score recalibration walker followed 
by variant calling. Variant quality score recalibration was completed using an additional 
172 sets of exomes from Amish individuals who were not members of nuclear family 1. 
Annotation of nucleotide variants was performed using the SeattleSeq Annotation 
server133. Variant filtration was completed as follows: variants found in the 1000 
Genomes project database, NHLBI exome sequencing project exome variation server 
(EVS) database, or dbSNP137 database were excluded. In addition, single nucleotide 
variants that were not missense, nonsense, splice junction, or frame shift causing 
mutations found within exon boundaries were excluded. Genes not known to be 
associated with AMD were also excluded. Variants found to be either homozygous or 
heterozygous and shared by all three affected siblings were retained. Variant 
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 confirmation was performed using standard forward and reverse Sanger sequencing 
practices on the ABI 3730xl. 
Targeted Genotyping:  
Genotyping was performed using the Sequenom MassARRAY genotyping 
platform (Sequenom, San Diego, USA). Independent Sequenom pools were genotyped 
and evaluated for the rare-variant data, and the 19 loci used to calculate the cumulative 
genetic risk score. A genotyping efficiency threshold of 95% was used in both datasets 
to determine a valid Sequenom assay. See table 4.2 for final sample sizes used in each 
step of the analysis.  
Association and Linkage Analysis:  
Variants identified in the nuclear family were evaluated for association with AMD 
in the full Amish dataset  using the Modified Quasi Likelihood Score statistic (MQLS)146. 
MQLS is comparable to the chi-square test with the exception that it estimates the 
variance on point estimates of the allele frequencies in cases and controls while taking 
into account the correlation between related individuals in a pedigree. This effectively 
allows all degrees of relationships to be included in the association analysis. Kinship and 
inbreeding coefficients for all possible relationships in the 13-generation pedigree were 
calculated using the MQLS recommended program KinInbcoef. MQLS analysis was 
performed using option 1, which allows for individuals with genotype, but no phenotype 
data to contribute to the analysis. An assumed disease prevalence of 10% was selected 
from published estimates of the prevalence of AMD in individuals over age 60 in 
population samples23, 131, 147. The nuclear family was genotyped as part of the full Amish 
dataset and was not excluded from the analysis. A sub-analysis was performed in which 
only those cases with a clinical exam completed by a retinal specialist were analyzed. 
Parametric linkage analysis was performed using the entire data set genotyped 
on the Affymetrix Human SNP Array 6.0. The pedigree was divided into smaller, more  
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 Table 4.2: Genotyped Samples Utilized per Analysis Step 
 
computationally feasible pedigrees using PedCut with a bit size threshold of 24148. 
Parametric heterogeneity log-of-odds (HLOD) scores were calculated under affecteds-
only dominant and recessive models assuming incomplete penetrance in MERLIN149. 
Under the dominant model, we specified penetrance values of 0 for no copies of the 
disease allele and 0.0001 for one or two copies of the disease allele. Under the 
recessive model, we specified penetrances of 0 for zero or one copy of the disease 
allele and 0.0001 for 2 copies of the disease allele. The disease allele frequency was set 
to 10% and marker allele frequencies corrected for relatedness were estimated from all 
genotyped Amish individuals. Multipoint linkage analysis was performed on a 7 
megabase region surrounding CFH. LD pruning for multipoint was performed using the 
HAPMAP CEPH samples with a pairwise r2 cutoff of < 0.16. In addition to standard 
multipoint linkage analysis, sub-analyses specifying liability classes modeled on the 
effect sizes of the rare and common CFH alleles were examined.  These included using 
the common SNP data derived from the Affymetrix 6.0 GWAS chip; assuming only CFH 
Y402H as a risk allele; assuming only CFH P503A as a risk allele, and assuming both 
CFH Y402H and P503A as risk alleles.   Detailed methods for quality control and linkage 
analysis procedures can be found elsewhere150. 
82 
 To examine linkage disequilibrium (LD) between the novel variant and the 
common Y402H variant, we extracted the most distantly related Amish subjects 
genotyped in the pedigree. For this analysis, we used a maximum pair-wise relationship 
cut-off between 2nd and 3rd cousins, resulting 168 individuals available for an LD 




Clinical vs. Self-Report of AMD: 
Comparing clinical diagnoses to self-report of AMD status in individuals for whom 
both were available, we observed positive and negative predictive values of 89% and  
90%, respectively (Table 4.3), indicating that self-report of AMD status is a good proxy 
for AMD diagnosis in this population sample.  
Cumulative Risk Score Analysis: In our cumulative genetic risk score analysis we 
observe a mean risk score of 1.12 (95% CI [1.10, 1.13]) in the Amish controls and 1.18 
(95% CI [1.13, 1.22]) in the Amish cases (p=0.0042; Figure 4.3). We also observe a 
mean risk score  
Table 4.3: AMD Self-report Pilot Study 
 
83 
 Figure 4.3: Cumulative Genetic Risk Score Analysis Across Amish and non-Amish Samples 
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of 1.14 (95% CI [1.13, 1.16]) in 841 non-Amish Caucasian controls and 1.31(95% CI 
[1.30, 1.32] in 1,573 non-Amish Caucasian cases. When comparing the Amish cases 
with the non-Amish cases we see a significant decrease in genetic risk score 
(p<0.00001; Figure 4.3).   
Exome Sequencing and Linkage Analysis: 
Exome sequencing was performed on the three individuals in family 1.  We 
generated on average 4.6 million reads per sample. 75% of reads were on target with a 
depth of coverage of 10X or higher.  We examined these data for rare variants in known 
AMD genes that might explain AMD in this family. After variant filtration procedures, we 
identified a single non-synonymous mutation in CFH that predicts a proline to alanine 
amino acid change at position 503 (P503A; Figure 4.4).  
Case-control analysis using self-reported affection status in the Amish sample 
population identified a significant association of AMD with P503A (p=9.27 x10-13). 
Results were consistent in the sub analysis of subjects with clinically confirmed AMD 
(p=5.21 x10-7). Out of the Amish samples that were not part of the original nuclear family 
and that were genotyped for the P503A variant, we observed 15 additional carriers of the 
P503A variant with 8 subjects affected, 5 unaffected, and 2 subjects of unknown case-
control status. When evaluating the variant in our non-Amish Caucasian dataset, we did 
not observe the risk allele in either the 791 controls or the 1,456 cases.  Multipoint 
linkage analysis carried out on chromosome 1 identified an HLOD peak of 5.12 on 
chromosome 1 spanning the CFH gene. After Incorporating a liability class for carriers of 
the CFH P503A rare variant we observe a maximum LOD score of 4.53 in this region; by 
including the common Y402H variant we observe a maximum LOD score of 3.72, when 
we include liability classes for carriers of both the common and rare CFH variants into 
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 the model, we observe a maximum HLOD score of 3.28 (Figure 4.5 A-D). Upon 
examination of LD between the Y402H variant and the P503A variant we observe an r2 
value of 0.002.  
 
Figure 4.4: Variant filtration procedures 
Fiftration steps used and the resultant number of variants after each stage. Variants 
passing quality control procedures are used as the initial filtration starting point. ESP 






We determined that the genetic burden of known AMD loci is substantially lower 
in the Amish than in the general European ancestry populations. Given that AMD is at 
least as frequent in the Amish as in other European ancestry populations (Dwight 
Stambolian, personal communication) and that the Amish generally do not smoke (the 
strongest known AMD environmental risk factor outside of age), our data support the 
hypothesis that other genetic loci are segregating in the Amish. 
We identified a densely affected nuclear Amish family in which affected siblings 
a-78, a79 and a-80 do not carry the Y402H or A69S risk variants in CFH and ARMS2 
respectively, loci that account for the majority of the genetic risk of AMD in Caucasian 
populations107. The absence of these risk alleles in affected members lead us to 
hypothesize that other rare variants of large effect may be contributing to AMD in this 
family. Using exome sequencing data, we identified a novel missense mutation that is 
shared among the affected siblings and located in the CFH gene. This mutation is a 
cytosine to guanine transversion resulting in the substitution of an alanine for a proline at 
amino acid position 503 (P503A).  The P503A locus has a Genomic Evolutionary Rate 
Profiling (GERP) score of 3.64, indicating strong conservation across mammalian 
species. PolyPhen2, which predicts the possible impact of amino acid substitutions on 




 Figure 4.5 A-D: Multipoint linkage Results on Chromsome 1 
Figure A. Native multipoint linkage results in region harboring CFH 
 
Figure 4.5 A-D: Multipoint linkage Results on Chromsome 1 
Figure B. Incorporation of the P503A variant as a covariate in the linkage analysis shows a 






 Figure 4.5 A-D: Multipoint linkage Results on Chromsome 1 
Figure C. Incorporation of the P503A variant as a covariate shows a reduction in the Maximum 




Figure 4.5 A-D: Multipoint linkage Results on Chromsome 1 
Figure D. Incorporation of both the common and rare variants as covariates shows a reduction in 




 CFH is a regulator of the alternative complement cascade and associations to 
variation in CFH have consistently been replicated in AMD linkage and association 
analyses46, 50, 55, 57, 134, 135. CFH inhibits activation of complement component 3 (C3) to 
C3a and C3b, and in addition direct inactivation of C3b. Previous work has shown 
binding sites for C3b in short consensus repeat (SCR) domains1-4, 6-10, and 16-20 of 
complement factor H151, 152. The P503A variant is located within SCR domain 8, and thus 
may affect C3b binding affinity. Expanding the analysis of this variant to the full Amish 
dataset, we observe a total of 19 carriers including the four carriers in the nuclear Amish 
family, 11 reported as having AMD, 6 reported not having AMD, and 2 with an unknown 
affection status. Of the 19 self-reported carriers, 6 had their diagnosis confirmed by a 
retinal specialist. 
Multipoint linkage analysis carried out across chromosome 1 shows an HLOD 
score above 5 within the region harboring the CFH rare and common Y402H variants. 
When including liability classes to account for these variants, we see a minimal reduction 
in the HLOD score, indicating that these variants may be only partially contributing to the 
observed linkage signal. Subsequent to the exome sequencing, 3 more members of the 
original nuclear family used to identify the P503A variant received a clinical diagnosis. Of 
these 3 subjects that originally self-reported as not having AMD, one individual, a-81, 
was seen by a retinal specialist and was reclassified as a case.  The self-report age of 
exam (AOE) of this individual was 66 and the clinical AOE was 74, suggesting that this 
individual may have progressed to a non-severe case during the eight year time-span 
between the self-report and clinical exam. Genotyping results of a-81 showed that this 
person was a non-carrier of the P503A variant, but did carry one copy of the Y402H risk 
allele (Figure 4.2). AOE is a concern with diagnosing AMD due to the variable age of 
onset, where no control can definitively be classified without some chance of 
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 progression to AMD. Our Amish study sample, although mainly classified through self-
report status, is well represented with late age controls matched to cases, an important 
factor in phenotype assignment for AMD (Table 4.2). Of the other two unaffected 
siblings, a-83 was a carrier of both the P503A variant and A69S, and presented with 
small drusen at the time of exam. This reaffirms the need for further molecular 
characterization of this variant and its role in the AMD pathway. 
Using the extensive genealogical data available in the AGDB, we observe that 
the carriers of this variant can be traced back four generations to a shared common 
ancestor and 15 of the 19 CFH rare variant carriers reside within Holmes County in Ohio 
(Figure 4.6).  We fail to observe the CFH P503A variant in 2,247 non-Amish individuals 
(1,456 non-Amish cases and 791 non-Amish controls) or in publicly available databases.  
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 Figure 4.6: Identification of the least common ancestor 
Identifying the least common ancestor that is a carrier of the P503A variant illustrated by the subject highlighted in yellow.  
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 This suggests that this CFH variant may have become enriched in the Ohio-Indiana 
Amish populations due to a recent founder event.  
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 Chapter V  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Age-related macular degeneration (AMD) is a debilitating, progressive disorder 
that has a large socioeconomic burden in the developed world with huge implications for 
current and future generations. As medical technology and healthcare standards 
continue to improve in both developed and developing countries, average life 
expectancy will increase. This growth will drive the incidence and prevalence of the 
disease to ever-increasing proportions. The increasing prevalence of AMD may be 
mitigated in the developed countries due to reduced rates of smoking, although this 
same trend is not currently seen in developing countries and it may become a growing 
factor for these countries. Understanding the genetic etiology of AMD and its relation to 
the multiple AMD phenotypes will have great implications for diagnosing and treating the 
disorder early enough in the disease process to preserve visual acuity. 
As explained in chapter I, AMD shows substantial phenotypic heterogeneity 
throughout all stages of disease. Individuals affected with AMD may present with as little 
as intermediate drusen throughout their lives and not progress pass this stage, while 
other individuals present with combinations of geographic atrophy (GA), wet-AMD and 
drusen. Subjects with AMD also show heterogeneity with their rate of disease 
progression for both GA and neovascular AMD. Interestingly, for a complex disease, the 
genetic contribution to AMD is estimated to be very high, and in some cases as high as 
70%69. This underlying genetic causality has led to great advances in the genetic study 
of AMD with linkage and association studies identifying replicable common variants that 
contribute upwards of 65% of the total genetic variation due to AMD.  
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 We have also learned that genetic risk, when assessed in AMD is difficult to 
dissect with respect to the phenotypes, as the major genetic risk factors such as CFH 
and ARMS2/HTRA1 trend in magnitude of effect depending on which of these 
phenotypes is being examined153. As an attempt to tease apart the phenotypic 
heterogeneity, we hypothesized that the major risk loci previously identified in genetic 
association analysis of AMD may in part explain drusen progression when treating 
drusen as a quantitative measure. To test this hypothesis it was necessary to take an 
imaging genetics approach using the major diagnostic measure, color fundus 
photographs, to extract drusen as a quantitative feature.  
In chapter II we introduce the Age-related Eye Disease Study dataset due to its 
tremendous scientific value and heavy use in chapter 3, and discuss the image quality 
control procedures we employed for our quantitative analysis. The value of the AREDS 
data is significant as subjects were followed in a structured clinical trial for over 12 years 
with fundus photographic images taken bi-annually, making it an ideal dataset for a 
longitudinal study of drusen progression. The necessity of high quality fundus photos is 
of great importance  to accurately quantify drusen load, mainly due to the phenotypic 
complexity of drusen in nature. Drusen can present as either soft or hard, leading to 
differences in size, number, color, border.  As such, we examined the effects of image 
quality extensively in both the dbGAP based AREDS dataset and the CWRU/HIHG 
dataset.  Based on manual review of digitized AREDS images, it was found that major 
quality issues were present and not well documented by dbGAP or AREDS.  
We found that the distribution of high quality images is significantly different 
between the AREDS and the CWRU/HIHG data even after manual review. We believe 
that these auto generated quality score differences may be in part an artifact of the 
digitization process that took place with the AREDS data. Image quality after manual 
review did not have statistically significant impact on drusen calling and therefore we did 
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 not take any additional steps with the quality information.  Although this conversion 
process was a concern for our study, previous work examining the potential impact of 
the image digitization process has shown that major differences are not present when 
comparing parameters such as color, contrast of the original images to the digitized 
images154. Although this may be the case, we observed a significant quality drop within 
the AREDS data, and due to these quality issues we dropped roughly 30% of images as 
deemed unfit for analysis. After extensive quality control, we identified 973 images of 
sufficient quality to put forward for automated drusen quantification.  
In chapter III we used the quality-controlled images to perform a quantitative 
genetic association analysis on drusen load. Under the assumption that the 19 common 
variants associated with AMD in the AMDGENE consortium study make up a bulk of the 
genetic variation contributing to AMD, we performed a hypothesis driven analysis 
examining these marker’s contribution to drusen progression. We structured our analysis 
to include only the period under which subjects presented with drusen only, in attempt to 
isolate the role that these 19 loci contribute to drusen progression.  To reduce 
heterogeneity in the dataset with respect to mean progression rates, we restricted our 
analysis to the first 6.5 years of follow-up data. Dropout of subjects due to advanced 
AMD progression led to an uneven representation of subjects at the end of the original 
12.5-year study, driving the mean progression rate to reflect only subjects that finished 
the study with drusen only. As this was the case, we found that 6.5 years was the 
optimal follow-up time for a representative distribution of endpoint severity of drusen 
only, GA, and wet AMD. 
We initially examined known non-genetic risk factors for their association with 
drusen progression. We did not observe sex, age, or smoking as contributing to drusen 
progression or baseline.  It could be argued that age and smoking should show some 
contribution to drusen progression or baseline, as they are strong risk factors for AMD.  
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 The absence of these associations in our results may be explained by the use of a case 
only approach in our analysis whereas these risk factors are typically enriched in case-
control analyses.  
Our primary genetic analysis was oriented toward using a genetic risk score to 
measure the cumulative effect of drusen load on baseline and progression. This allowed 
us to test a single hypothesis that cumulative genetic load contributes to drusen 
progression. Our results from the cumulative genetic risk score analysis showed a small 
contribution to baseline drusen load, but no association with drusen progression. It is 
important to note that the effect sizes used in the cumulative genetic risk score analysis 
were based on the results of the AMDGENE consortium which was assessing risk of 
disease, not progression of disease. In their analysis, the authors treated AMD 
phenotype status based on the presence or absence of disease, lumping intermediate 
AMD, geographic atrophy and wet AMD into one category. It is possible that these effect 
sizes do not effectively translate to just the intermediate phenotype of drusen only.  
To test this, we also examined the 19 loci that make up the genetic risk score 
individually.  Of these variants, the variant located at the VEGFA locus showed a 
nominal association with drusen progression in the AREDS dataset, although we were 
not able to replicate these results in the CWRU/HIHG dataset. VEGFA mRNA and 
protein are both enriched in drusen and are a factor in angiogenesis and inflammation. 
Again, this highlights the complicated interplay between the three phenotypic 
manifestations of AMD, with inflammation potentially relating to drusen biogenesis and 
angiogenesis relating to wet AMD. The major risk variant in CFH and ARMS2 were not 
significantly associated with drusen progression or baseline. Interestingly, when we 
examine the intercepts for the CFH risk variant we see an apparent dominant pattern of 
effect in the AREDS data. This observation is also present in the CWRU/HIHG dataset, 
although the coefficients are not significant in either analysis. Under a dominant model, 
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 we observe an allelic association with CFH when performing a Wilcoxon rank-sum test 
on drusen area at baseline in the AREDS sample (p=0.028). Again, we need to be 
critical of these results as this is not multiple test corrected. 
The potential dominant effect of the CFH risk variant may be alluded to based on 
prior linkage analyses carried out by Klein et al. and Weeks et. al, which showed the 
CFH locus segregating in a dominant fashion with AMD44, 155. In the characterization of 
the AMD phenotype, the authors used soft drusen, GA, and neovascular AMD as their 
definitions of AMD. With the presence of multiple phenotypes for a case-control based 
diagnosis, it may be that the mode of inheritance is phenotype dependent.  To further 
this analysis it would be ideal to test this in a larger sample. AREDS has recently made 
fundus photo data available on all subjects within the clinical trial on a single time point. 
This would give us the power to both see the possible dominant effect observed in our 
smaller datasets, and to see whether CFH truly contributes an allelic effect to baseline 
drusen. 
To explore the role of unknown genetic variation to drusen progression, we used 
the data from the exome-chip based quantitative GWAS to perform a pathway analysis 
with the software package PARIS, using genes from the KEGG database. Our most 
highly significant pathway in the AREDS dataset was the cell-adhesion molecule 
pathway which is associated with inflammation (CAM; p-value < 0.0001). Through 
interrogation of the 127 genes that make up this pathway, we identify three genes driving 
the signal. These genes are neurofascin (NFASC) on chromosome 1, CD226 molecule 
(CD226) on chromosome 18, and neurexin 1 (NRXN1) on chromosome 2. CD226, which 
is the strongest associated driver gene in this analysis has been linked to regulation of 
proinflammatory responses and CD antigens have been reported as a drusen 
component3, 156. The statistical significance of these genes was confirmed using the 
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 gene enrichment program “Versatile Gene-based Association Study” (VEGAS; Appendix 
D). 
Future studies examining drusen progression are still needed. A critical 
observation that we made during the course of the study was the high level of intra-
subject variation in the repeated measure data, and the inter-subject variation of 
subject’s baseline and progression rates. With drusen presenting with such complicated 
manifestations in color fundus photos, accurate quantification leaves room for 
improvement. It may be possible to reduce some of this variation by taking advantage of 
newer imaging technologies. One technology that is now being used for the clinical 
diagnosis of AMD is optical-coherence tomography (OCT). OCT allows the user to 
generate a 3-dimensional image of the RPE layer, allowing quantitative information to be 
collected on both drusen area and volume. The collection of this quantitative information 
may allow for better representation of the role of genetic variants in the natural history of 
drusen development. Current studies examining the correlation of OCT and fundus 
photography show reduced variation in OCT, although the identification of smaller 
drusen is stronger in color fundus photographs157.  This observation may complicate 
matters even more as it again highlights the complexities of drusen analysis.  We may 
find that it is necessary to integrate major imaging modalities such as OCT and color 
fundus photography together to accurately capture this AMD phenotype. 
A natural observation in examining changes in drusen area over time are 
instances of spontaneous drusen regression. Drusen regression typically has been 
shown to precede the manifestation of GA and wet AMD. Although not significant in our 
analysis, we do observe a reduced slope in subjects that exit the study with wet AMD as 
compared to subjects that exit the study with GA or drusen only. Our AREDS data, 
although extensive, is limited by the time between visits that fundus photographs were 
taken and thus we do not have the resolution to characterize this phenomenon in our 
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 samples. Although we had available more frequent visit data in the CWRU/HIHG set, the 
number of samples with this outcome data was limited.  
Understanding the implications of drusen regression and its potential as an 
indicator for advancement to GA and wet AMD could benefit from quantitative drusen 
analysis. Some work has alluded to the role of drusen location and its potential effect on 
risk for AMD advancement158. These data were presented in the context of whether 
drusen found in the inner or outer rings of the grading grid play a role in progressing to 
advanced AMD158.  By examining this spatial and temporal relationship between drusen 
and the advanced stages of disease, we may be able to better understand the 
mechanisms involved in drusen associated disease advancement at the site of insult. 
To understand the genetic contribution of rare-variants to AMD, we examined the 
Amish populations of Ohio and Indiana in Chapter IV.  Through exome sequencing of a 
highly penetrant nuclear Amish family we were able to identify a rare non-synonymous 
CFH variant (P503A) that is predicted to be damaging. We observed a significant 
genetic association of P503A when we expanded our analysis to include all subjects in 
our Amish sample. This association signal is complemented by a linkage scan across 
the CFH locus, which shows that the P503A variant has some contribution to the overall 
linkage peak. This variant was not observed in a cohort of 1,400 non-Amish subjects. 
We recently genotyped 700 subjects from the Pennsylvania Amish community and do 
not observe the P503A variant in this population either, leading us to surmise that this is 
a founder mutation specific to the Ohio and Indiana Amish. We must note we do not 
have phenotype data on the 700 Pennsylvania Amish subjects and thus this distribution 
of cases and controls is unknown. 
Important to the future study of our Amish cohort for AMD is better 
characterization of the phenotype data. Our current dataset relies on self-report 
diagnostic information to describe AMD case status. The results of our self-report study 
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 were promising in that this measure may serve a purpose, as a surrogate for the 
assignment of case-control status for our AMD related studies, but true diagnoses by a 
retinal specialist is a necessity considering the phenotypic complexities of the disease. 
Also of importance to the Amish AMD studies is discovering the missing genetic 
contribution to AMD. Our risk score analysis showed reduced genetic risk based on the 
known 19 common variants, and the rare CFH variant only appears to explain some of 
that unknown genetic risk.  Understanding the unknown common and rare genetic 
burden of disease will need to be further explored.  
In conclusion, AMD continues to be a valuable complex disease for genetic 
studies due to its high heritability and its socioeconomic impact. Although a large 
proportion of the genetic variation explained by AMD has been identified, its contribution 
is largely put in the context of disease risk. Many of the current studies examining 
progression are focused on binary outcomes trying to understand the impact of 
progressing from early to late AMD with little effort put towards understanding rate of 
progression.  Elucidation of potential rare and common genetic contributors for AMD rate 
of progression may lead to better understanding of the mechanisms involved in AMD 
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 Appendix B: Tabulated Results of Top Progression Quantitative GWAS Hits 
CHR SNP BP BETA AREDS P-value AREDS P-value CWRU / Miami 
1 rs2069084 234984988 -0.02518 1.52E-06 0.2582 
2 exm279714 238668783 -0.03331 6.16E-06 0.5632 
7 rs10226466 96357756 0.02789 1.27E-05 0.269 
17 rs8077882 72145172 0.01507 1.37E-05 0.8151 
6 rs6568924 116596247 -0.01717 1.66E-05 0.6334 
2 rs10203272 86033879 -0.02126 1.71E-05 0.9214 
6 rs6911639 32978178 0.0181 2.33E-05 0.2415 
5 rs425203 57917792 -0.0154 2.39E-05 0.9321 
5 rs4304068 158976183 -0.01736 2.42E-05 0.2061 
7 rs395158 9216593 0.0179 4.01E-05 0.4838 
8 rs1546745 90545792 0.01459 4.44E-05 0.3766 
17 rs7214008 72148066 -0.01503 4.77E-05 0.8671 
8 rs7846085 90528845 0.01457 4.80E-05 0.3766 
8 rs11786321 90409007 0.01424 4.83E-05 0.2956 
8 rs12544520 90407910 -0.01721 4.91E-05 0.26 
1 rs12737855 204912843 -0.01653 4.93E-05 0.1352 
4 rs2011590 38944101 0.01425 5.20E-05 0.1997 
1 rs2796160 234966277 -0.02238 6.60E-05 0.2933 
8 rs10956094 90478557 0.0141 6.77E-05 0.3588 
5 rs1428609 66680616 0.01369 6.89E-05 0.3383 
8 rs1386648 90539951 0.01428 7.25E-05 0.299 
6 exm573430 116575116 0.02026 8.51E-05 0.9273 
20 rs6127826 55307132 0.02811 8.60E-05 0.7405 
8 rs1510465 90576635 0.01449 8.72E-05 0.3571 
13 rs9582867 105099441 0.01696 0.0001048 0.04434 
14 rs2236135 23595721 -0.01813 0.0001204 0.9356 
13 rs111689935 31787926 0.02324 0.0001213 0.499 
8 rs9297680 90597465 -0.01393 0.0001257 0.4882 
16 rs11861081 8321930 0.01555 0.0001276 0.6308 
13 rs9552533 22454710 -0.02904 0.0001465 0.1968 
7 exm2270701 137089307 -0.01356 0.0001477 0.01182 
18 rs7228563 71408712 0.01327 0.0001595 0.004997 
6 rs62414126 116460264 0.02534 0.0001631 0.6724 
7 rs3919487 144955976 -0.01428 0.0001867 0.2857 
6 rs62414146 116561087 0.02476 0.0001993 0.6724 
22 rs9606708 30646126 0.01401 0.0001996 N/A 
1 rs11590192 231922845 -0.01296 0.0002128 0.688 
13 rs4641600 110500338 -0.01506 0.0002156 0.06816 
2 rs3943477 5224268 0.0159 0.0002196 0.1723 
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 18 rs12956584 72348611 0.01772 0.0002245 0.9689 
3 kgp11084897 128562396 0.02877 0.0002341 0.5946 
3 rs234044 172313268 -0.0132 0.0002419 0.5018 
6 rs850577 97365239 0.01467 0.0002424 0.09543 
15 rs7178749 62053897 -0.01326 0.0002528 0.1125 
12 rs427244 124605287 0.01663 0.0002583 0.1506 
17 rs11652016 49570481 -0.01308 0.0002601 0.1479 
1 rs17014713 111763153 0.02159 0.0002635 0.6172 
8 rs6981722 138769527 0.01362 0.0002641 0.3081 
2 rs9288260 197127830 0.02196 0.0002642 0.8317 
14 rs10138170 22279576 0.01438 0.0002658 0.9963 
1 rs10923507 118731761 -0.01418 0.0002667 0.6933 
2 rs6729441 217048565 0.02185 0.0002672 0.8764 
2 rs7583902 217057937 0.02185 0.0002672 0.8764 
2 rs1051685 217070376 0.02185 0.0002672 0.8764 
10 rs2590289 60059641 -0.01952 0.000269 0.7631 
21 rs9978712 17820112 0.01364 0.0002711 0.4424 
19 rs17216041 19366643 -0.01549 0.0002855 0.579 
2 rs13407838 113745428 -0.01763 0.0002875 0.4538 
1 rs17257729 118678953 -0.01311 0.0002905 0.9516 
18 rs1942467 70517206 -0.0249 0.0002906 0.684 
10 rs7895100 87683328 0.01725 0.0002926 0.7544 
13 rs11620257 31776738 0.02208 0.0002965 0.1885 
4 rs13115030 87296065 -0.01634 0.0002975 0.1542 
6 rs12527153 116491302 0.02386 0.0002988 0.7087 
4 rs16891600 15210390 -0.02538 0.0003037 0.6155 
5 rs6450023 68526063 0.01457 0.0003099 0.378 
15 rs7162855 58811252 -0.02107 0.00031 0.9917 
18 rs1474128 24992045 0.0126 0.0003168 0.9928 
20 rs6060989 30429763 -0.01568 0.0003181 0.5371 
4 rs17751557 87834607 0.01626 0.0003228 0.8545 
12 rs7138639 98538264 0.01271 0.0003228 0.2455 
1 rs4411121 118757034 -0.01393 0.0003266 0.892 
4 rs11097109 87269343 -0.01617 0.000327 0.1861 
9 rs11142863 74135468 -0.01849 0.0003278 0.6431 
4 rs10050311 87754419 0.01756 0.0003336 0.295 
13 rs9513993 102861383 -0.02876 0.0003357 0.8503 
1 rs4325188 105700935 -0.01396 0.0003359 0.1898 
1 rs6427122 168274691 0.01333 0.0003403 0.03495 
8 rs11780016 90601100 0.015 0.000343 0.7974 
3 rs9860340 87783976 0.0158 0.0003449 0.1326 
111 
 10 rs946516 80609135 -0.01367 0.0003454 0.6136 
19 rs1064395 19361735 -0.01523 0.0003464 0.579 
11 rs10837204 39671205 0.01472 0.0003519 0.9432 
5 rs11134701 170972663 0.01995 0.0003526 0.6288 
18 rs1144081 50087903 0.01435 0.0003638 0.002056 
17 rs4792394 13684917 -0.01253 0.0003666 0.5361 
10 rs6482124 18298132 -0.01602 0.0003768 0.1063 
8 rs13282836 26678206 -0.01568 0.0003821 0.3995 
2 rs1453780 5226989 0.01575 0.0003853 0.1755 
6 rs883273 154630541 -0.0133 0.0003996 0.9036 
5 rs7717348 95407894 0.01402 0.0004097 0.7824 
11 rs518119 124181158 0.01855 0.0004125 0.5714 
10 rs7073090 59943234 -0.01982 0.0004196 0.6953 
6 rs6912724 144814016 -0.01395 0.0004217 0.01083 
18 rs1144076 50079024 0.0147 0.000425 0.002048 
8 rs7825497 714648 0.01757 0.0004391 0.3271 
4 rs6849805 84626069 -0.0159 0.0004406 0.3539 
7 rs7776689 96162825 0.01485 0.0004504 0.904 
2 rs4674761 224071098 -0.01586 0.0004671 0.7444 
11 rs12788923 37083616 -0.01303 0.0004681 0.9554 
7 rs6963647 96170054 0.01537 0.0004707 0.9852 
11 rs1503932 11206934 0.01251 0.0004772 0.8493 
9 rs12375980 11178672 -0.01255 0.00049 0.7574 
10 rs7900951 133657703 -0.0135 0.0004932 0.1942 
4 rs6819155 87976178 0.01537 0.0004941 0.9198 









 Appendix C: Tabulated Results of Top Pathways from Paris 










197335 hsa04514 2277 Cell adhesion molecules (CAMs) 0.0001 
197353 hsa04670 1686 Leukocyte transendothelial migration 0.00055 
197306 hsa03450 127 Non-homologous end-joining 0.0008 
197277 hsa00780 37 Biotin metabolism 0.0011 
197268 hsa00640 392 Propanoate metabolism 0.0016 
197361 hsa04810 2502 Regulation of actin cytoskeleton 0.005 
197333 hsa04510 2848 Focal adhesion 0.00655 
197343 hsa04621 484 NOD-like receptor signaling pathway 0.00685 
197379 hsa05210 1034 Colorectal cancer 0.0078 
197292 hsa02010 649 ABC transporters 0.00875 
197381 hsa05212 782 Pancreatic cancer 0.00885 
197378 hsa05200 4423 Pathways in cancer 0.0094 
197314 hsa04110 1009 Cell cycle 0.0138 
197209 hsa00052 321 Galactose metabolism 0.0161 
197283 hsa00903 143 Limonene and pinene degradation 0.01805 
197391 hsa05222 1272 Small cell lung cancer 0.0194 
197389 hsa05220 837 Chronic myeloid leukemia 0.02695 
197279 hsa00790 105 Folate biosynthesis 0.0278 
197336 hsa04520 1446 Adherens junction 0.0285 
197269 hsa00650 347 Butanoate metabolism 0.02895 
197350 hsa04662 943 B cell receptor signaling pathway 0.03055 
197380 hsa05211 773 Renal cell carcinoma 0.0325 
197227 hsa00280 485 Valine, leucine and isoleucine degradation 0.0335 
197265 hsa00604 260 Glycosphingolipid biosynthesis - ganglio series 0.0379 
197344 hsa04622 459 RIG-I-like receptor signaling pathway 0.0385 
197331 hsa04360 2345 Axon guidance 0.04635 







 Appendix D: Tabulated Results of Gene Enrichment Analysis (VEGAS)  
Table is based on AREDS quantitative GWAS results. 
 
CHR Gene # SNPs Start Stop P-value 
6 BRD2 16 33044414 33057260 2.00E-04 
20 DUSP15 9 29912530 29922140 0.000363 
6 HLA-DOA 20 33079937 33085367 0.000449 
22 NAGA 1 40784283 40796792 0.000524 
22 FAM109B 3 40800200 40805388 0.000674 
22 C22orf32 3 40805644 40810234 0.000677 
22 NDUFA6 3 40811475 40816834 0.000681 
20 C20orf3 7 24891579 24921425 0.000725 
19 TM6SF2 7 19236173 19245074 0.000742 
20 C20orf3 7 24891579 24921425 0.000744 
19 HAPLN4 7 19227470 19234560 0.000761 
20 TPX2 5 29790564 29853264 0.000773 
17 TBC1D3E-1 1 33358341 33369482 0.000817 
17 TBC1D3-1 1 33358400 33369299 0.000834 
17 TBC1D3E-1 1 33358341 33369482 0.000844 
17 TBC1D3F-1 1 33358341 33369482 0.000867 
19 NCAN 11 19183781 19224061 0.000874 
22 CYP2D6 6 40852444 40856827 0.001008 
20 CST7 7 24877865 24888562 0.001022 
16 SHCBP1 1 45171968 45212812 0.001034 
1 SPAG17 12 118297810 118529357 0.001073 
16 VPS35 3 45251089 45280645 0.001095 
19 SF4 8 19248321 19292307 0.001159 
7 SHFM1 7 96156014 96177139 0.00116 
20 FOXS1 8 29895763 29897081 0.001162 
22 C1QTNF6 18 35906151 35914276 0.00146 
22 TCF20 8 40885962 40941389 0.001509 
10 IPMK 5 59625619 59697700 0.00155 
21 SIM2 13 36993860 37044380 0.001567 
18 CD226 8 65681172 65775212 0.001568 
20 MYLK2 7 29870838 29886161 0.001591 
1 F11R 12 159231624 159257757 0.001726 
7 FLJ43692 2 143514609 143523669 0.001824 
11 METT5D1 6 28086373 28311630 0.00185 
22 WBP2NL 6 40724737 40754423 0.00209 
1 CTNNBIP1 3 9830920 9892903 0.00214 
7 CTAGE4-1 2 143511480 143514106 0.00219 
11 KIF18A 5 27998738 28086322 0.002272 
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 20 BCL2L1 6 29715921 29774317 0.00232 
6 TSPYL4 14 116677823 116681954 0.00237 
22 GSTT1 2 22706138 22714284 0.002373 
4 PTPN13 9 87734908 87955326 0.00241 
6 TSPYL1 14 116704438 116707973 0.002444 
21 KRTAP20-2 5 30929453 30929651 0.00245 
11 OR8G1 7 123625632 123640966 0.00248 
6 DSE 26 116707975 116866135 0.00253 
20 TTLL9 12 29922165 29994519 0.00254 
14 SIX4 2 60246008 60260545 0.002559 
11 OR8G5 7 123639932 123640973 0.00259 
1 RBBP5 11 203322601 203357754 0.00262 
4 C4orf36 9 88016381 88032599 0.00263 
18 WDR7 32 52469613 52848034 0.00264 
21 KRTAP20-1 5 30910644 30910815 0.00264 
1 ITLN2 11 159181439 159191213 0.0027 
7 RARRES2 9 149666350 149669639 0.00282 
12 NEDD1 8 95825374 95870172 0.00287 
7 C7orf29 9 149657870 149660743 0.00288 
7 LRRC61 10 149651537 149666172 0.00288 
22 LOC652968 6 29011106 29015616 0.00313 
4 ATOH1 12 94969100 94970165 0.00314 
7 REPIN1 10 149696811 149702066 0.003148 
10 REEP3 10 64951128 65051978 0.003183 
14 SGPP1 1 63220687 63264509 0.00319 
22 TBC1D10A 8 29017978 29052894 0.003259 
21 KRTAP20-3 4 30937053 30937326 0.003387 
22 OSM 6 28988818 28992840 0.0034 
8 FAM164A 6 79740884 79792490 0.003615 
19 GATAD2A 5 19357641 19480741 0.00383 
19 RASGRP4 5 43591537 43608785 0.00387 
22 C22orf26 5 44825002 44828688 0.00389 
14 MNAT1 6 60271222 60505151 0.00391 
6 C6orf154 3 43582684 43586402 0.00392 
12 KRT78 16 51519012 51529045 0.00395 
12 KRT8 14 51577237 51585127 0.00397 
5 C5orf39 5 43074938 43076098 0.00398 
1 PLA2G4A 20 185064654 185224736 0.00412 
11 OR8D2 10 123694367 123695303 0.00423 
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